US6203802B1 - Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process - Google Patents
Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process Download PDFInfo
- Publication number
- US6203802B1 US6203802B1 US08/195,081 US19508194A US6203802B1 US 6203802 B1 US6203802 B1 US 6203802B1 US 19508194 A US19508194 A US 19508194A US 6203802 B1 US6203802 B1 US 6203802B1
- Authority
- US
- United States
- Prior art keywords
- nanoparticles
- oil
- company
- sold
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 210000002615 epidermis Anatomy 0.000 title claims abstract description 16
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 210000003491 skin Anatomy 0.000 title claims description 33
- 230000000699 topical effect Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 7
- 239000002105 nanoparticle Substances 0.000 claims abstract description 110
- 239000003921 oil Substances 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- -1 alkyl cyanoacrylate Chemical compound 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims abstract description 13
- 230000009471 action Effects 0.000 claims abstract description 12
- 229920001651 Cyanoacrylate Polymers 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 42
- 239000006185 dispersion Substances 0.000 claims description 39
- 235000019198 oils Nutrition 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 22
- 229940087168 alpha tocopherol Drugs 0.000 claims description 20
- 229960000984 tocofersolan Drugs 0.000 claims description 20
- 235000004835 α-tocopherol Nutrition 0.000 claims description 20
- 239000002076 α-tocopherol Substances 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 12
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 10
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 10
- 229940042585 tocopherol acetate Drugs 0.000 claims description 10
- 229920002545 silicone oil Polymers 0.000 claims description 9
- 210000000434 stratum corneum Anatomy 0.000 claims description 7
- 229920002988 biodegradable polymer Polymers 0.000 claims description 6
- 239000004621 biodegradable polymer Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- 239000002199 base oil Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Chemical compound 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000007762 w/o emulsion Substances 0.000 claims description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 3
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 3
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 3
- ZGIGZINMAOQWLX-NCZFFCEISA-N 3,7,11-Trimethyl-2,6,10-dodecatrienyl acetate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COC(C)=O ZGIGZINMAOQWLX-NCZFFCEISA-N 0.000 claims description 3
- ZGIGZINMAOQWLX-UHFFFAOYSA-N Farnesyl acetate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOC(C)=O ZGIGZINMAOQWLX-UHFFFAOYSA-N 0.000 claims description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 3
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 claims description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 3
- 229940036350 bisabolol Drugs 0.000 claims description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229940043259 farnesol Drugs 0.000 claims description 3
- 229930002886 farnesol Natural products 0.000 claims description 3
- 229940007703 farnesyl acetate Drugs 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229940049918 linoleate Drugs 0.000 claims description 3
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 229920005597 polymer membrane Polymers 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019487 Hazelnut oil Nutrition 0.000 claims description 2
- 241000446313 Lamella Species 0.000 claims description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 206010040829 Skin discolouration Diseases 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 239000000058 anti acne agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124340 antiacne agent Drugs 0.000 claims description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001214 clofibrate Drugs 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007854 depigmenting agent Substances 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 2
- 229940031016 ethyl linoleate Drugs 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000010468 hazelnut oil Substances 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 239000003410 keratolytic agent Substances 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 238000003756 stirring Methods 0.000 description 20
- 239000004094 surface-active agent Substances 0.000 description 20
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 229920001993 poloxamer 188 Polymers 0.000 description 17
- 239000003755 preservative agent Substances 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 13
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 13
- 229950010048 enbucrilate Drugs 0.000 description 13
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 11
- 230000002335 preservative effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 10
- 239000002304 perfume Substances 0.000 description 9
- 238000001246 colloidal dispersion Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000265 homogenisation Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 206010015946 Eye irritation Diseases 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 231100000013 eye irritation Toxicity 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000002088 nanocapsule Substances 0.000 description 5
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 5
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 5
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 5
- 229940083466 soybean lecithin Drugs 0.000 description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- UKHVLWKBNNSRRR-ODZAUARKSA-M dowicil 200 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C\C=C/Cl)C3 UKHVLWKBNNSRRR-ODZAUARKSA-M 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000008132 rose water Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 0 *COC[H] Chemical compound *COC[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- HFQQYIUTYJVYFZ-UHFFFAOYSA-N 4-methylpentyl 2-cyanoprop-2-enoate Chemical compound CC(C)CCCOC(=O)C(=C)C#N HFQQYIUTYJVYFZ-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BQCMEGDXXJXJDW-UHFFFAOYSA-N CCC(C)OC.COCC(C)C Chemical compound CCC(C)OC.COCC(C)C BQCMEGDXXJXJDW-UHFFFAOYSA-N 0.000 description 1
- FOWCYVRGLNZOSA-UHFFFAOYSA-N CCC.CCC(CO)OC.COCC(C)CO.COCO Chemical compound CCC.CCC(CO)OC.COCC(C)CO.COCO FOWCYVRGLNZOSA-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- FYFBAZOROQDDTN-UHFFFAOYSA-N [3-(2-ethylhexoxy)-2-hydroxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COCC(CC)CCCC FYFBAZOROQDDTN-UHFFFAOYSA-N 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000001764 biostimulatory effect Effects 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CYFHLEMYBPQRGN-UHFFFAOYSA-N ditetradecyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCC CYFHLEMYBPQRGN-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- JWJWCXLQQIRUOY-UHFFFAOYSA-N octadecyl 2,3-dihydroxypropanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(O)CO JWJWCXLQQIRUOY-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical group 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000003748 selenium group Chemical class *[Se]* 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/017—Mixtures of compounds
- C09K23/018—Mixtures of two or more different organic oxygen-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/16—Amines or polyamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- the present invention relates to a composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis, by topical application of the said compositicn to the skin, and a preparation process for obtaining it.
- oils which are active and/or which contain an active ingredient.
- These oils are used as they are or, more often, in the form of a water-in-oil or oil-in-water emulsion.
- These oils are known to have an action on the surface of the skin, but also in the upper layers of the epidermis, since they pass through the stratum corneum, the cosmetic and/or pharmaceutical action of the oils generally increasing in efficacy with an increase in the proportion of oil penetrating into the upper layers of the epidermis.
- nanoparticles are known: this name is used to denote colloidal particles of the order of 10 to 1,000 nm in size consisting of polymeric materials, in which an active principle is trapped, encapsulated and/or adsorbed (see J. KREUTER, J. MICROENCAPSULATION 1988, Vol. 5, pages 115-127).
- the term nanoparticles can be used to denote nanospheres and nanocapsules: a nanosphere constitutes a porous solid polymer matrix on which the active ingredient is adsorbed; a nanocapsule is a polymer membrane surrounding a core consisting of the active principle.
- nanoparticles will be strictly limited to nanocapsules defined above.
- biodegradable materials are preferably selected in order to enable the said nanoparticles to be used therapeutically. It is known that cyanoacrylates, and especially polyalkyl cyanoacrylates, enable biodegradable nanoparticles to be obtained; the preparation of nanoparticles from cyanoacrylates is described in EP-B-0,007,895 and EP-B-0,064,967.
- biodegradable nanoparticles encapsulating biologically active compounds has been proposed in many therapeutic applications for many active principles, such as antimitotic or antineoplastic substances, antibiotics, hormonal substances, insulin, heparin or biological products such as proteins, antigens or the constituents of viruses, bacteria or cells. It has hence already been proposed to administer nanoparticles encapsulating active principles orally, subcutaneously, intradermally, intramuscularly, intravenously and by application to the eye (see EP-B-0,007,895, EP-B-0,064,967, FR-B-2,604,903, DE-A-3,722,837, DE-A-3,341,001 and FR-B-2,304,326).
- nanoparticles of cyanoacrylate encapsulating an oil or an active substance dispersed in an oil have been described, and it is specified that these nanoparticles can be administered orally, subcutaneously, intradermally, intramuscularly or intravenously.
- the use of nanoparticles for encapsulating perfumes has been described, the encapsulated perfumes having the advantage of causing the perfume odor to persist longer after application than in the case where the perfume is applied to the skin without encapsulation; encapsulation hence has a delay action on the perfume.
- the desired action of the perfume takes place at the surface of the skin, and the persistence of the odor is completely independent of the fate of the fraction of the nanoparticles which might possibly pass through the stratum corneum.
- This topical application hence provides no information as to the possible capacity of the nanoparticles to pass through the stratum corneum and to be degraded in the upper layers of the epidermis; it leads, on the contrary, to the prediction that the nanoparticles would remain predominantly at the surface of the skin, since they permit release of the perfume.
- nanoparticles were, on the one hand capable of passing through the stratum corneum in significant amounts, and on the other hand capable of releasing the active ingredient very rapidly into the upper layers of the epidermis.
- the encapsulation of an active oil (or one containing an active ingredient) in nanoparticles produced, surprisingly, an immediate action of the composition.
- the delay effect reported for the perfuming compositions applied topically in the document FR-A-2,515,960 cited above led those skilled in the art to anticipate that a topical application, assuming it to be capable of having an effect, could have only a delayed action.
- the invention hence proposes a composition whose properties are unexpected. Moreover, these properties are especially well suited to topical administration, as was shown in a comparative in vitro study of percutaneous absorption.
- the subject of the present invention is consequently a composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis, by topical application to the skin, characterised in that it comprises, in a suitable vehicle, biodegradable polymer nanoparticles encapsulating at least one active ingredient in the form of an oil and/or at least one active ingredient contained in an inactive carrier oil or an active oil, the active ingredient being selected from those having a cosmetic and/or pharmaceutical action.
- the nanoparticles used are preferably between 10 and 1000 nm, and more especially between 50 and 500 nm, in size.
- the weight of the nanoparticles loaded with at least one active ingredient advantageously constitutes from 0.1% to 20% of the total weight of the composition, and preferably from 0.5 to 5%. by weight.
- the polymers constituting the biodegradable nanoparticles can be polymers of C 2 -C 12 , and especially C 2 -C 6 , alkyl cyanoacrylate; the alkyl radical is preferably selected from the group composed of ethyl, n-butyl, hexyl, isobutyl and isohexyl radicals.
- the biodegradable polymers may also be taken from the group composed of poly-L-lactides, poly-DL-lactides, polyglycolides, polycaprolactones, polymers of 3-hydroxybutyric acid and the corresponding copolymers, such as copoly(DL-lactides/glycolides), copoly(glycolides/caprocolatones) and the like.
- nanoparticles obtained from poly-L-lactides, poly-DL-lactides and copoly(DL-lactides/glycolides) is especially advantageous, since the products of enzymatic or chemical biodegradation of these nanoparticles can themselves have cosmetic effects: thus, lactic acid exhibits humectant and plasticising properties; and glycolic acid exhibits depigmenting and/or biostimulatory properties.
- the active ingredients in the form of an oil are preferably selected from the group composed of ⁇ -tocopherol, ⁇ -tocopherol acetate, triglycerides rich in linoleic and/or linolenic acid(s), pentaerythritol tetra(2-ethylhexanoate), clofibrate, tocopherol linoleate, fish oil, hazelnut oil, bisabolol, farnesol, farnesyl acetate, ethyl linoleate and ethylhexyl para-methoxycinnamate.
- the inactive carrier oils are preferably selected from the group composed of triglycerides, simple or modified, especially by oxyethylenation, volatile silicone oils and mixtures thereof.
- any active ingredient capable of having a cosmetic or therapeutic activity can be, inter alia, emollients, humectants, free radical-inhibiting agents, anti-inflammatories, vitamins, depigmenting agents, anti-acne agents, antiseborrhoeics, keratolytics, slimming agents, skin coloring agents and sunscreen agents, and in particular linoleic acid, retinol, retinoic acid, ascorbic acid alkyl esters, polyunsaturated fatty acids, nicotinic esters, tocopherol nicotinate, unsaponifiables of rice, soybean or shea, ceramides, hydroxy acids such as glycolic acid, selenium derivatives, antioxidants, ⁇ -carotene, ⁇ -ori
- the active ingredient is preferably an oleophilic active ingredient in the form of a solution in the oil. However, it can also be in the form of a dispersion, suspension or emulsion.
- the weight ratio of the biodegradable polymer of the nanoparticles to the active oily phase is preferably between 0.05 and 0.5, and in particular in the region of 0.2.
- compositions according to the invention can take the form of a physiological fluid, a lotion, an aqueous, aqueous-alcoholic or oily gel or a water-in-oil or oil-in-water emulsion, or alternatively of aqueous dispersions of vesicles in which the constituent lipids are ionic or nonionic lipids or a mixture of ionic and nonionic lipids, with or without an oily phase.
- this type of product requires the introduction of a large amount of emulsifier in the case where it is desired to introduce unencapsulated oily active ingredients into them, and it is well known that emulsifiers have the effect of irritating the skin and are not compatible with all active ingredients.
- compositions can contain, in addition to the nanoparticles, known cosmetically and/or pharmaceutically acceptable adjuvants, such as fats, vaseline, preservatives, thickening agents, colorings and perfumes.
- known cosmetically and/or pharmaceutically acceptable adjuvants such as fats, vaseline, preservatives, thickening agents, colorings and perfumes.
- an interfacial polymerisation of a microemulsion of oil in an aqeuous-alcoholic medium is performed, as described, for example, in FR-A-2,515,960, by injecting, into an aqeuous phase containing or otherwise one surfactant, a mixture consisting of the oil(s) to be encapsulated, at least one (C 2 -C 12 ) alkyl cyanoacrylate and at least one solvent which can contain one surfactant, then evaporating off the solvent and optionally concentrating the aqueous dispersion of nanoparticles obtained.
- the solvent used is, more often than not, a C 2 -C 4 lower alcohol, especially ethanol, propanol, isopropanol or a mixture of these alcohols, or alternatively acetone; it can optionally contain one surfactant.
- the nanoparticles are obtained by precipitation of the polymer around a dispersion of oily droplets, by injecting, into an aqueous phase containing or otherwise one surfactant, a mixture consisting of the oil(s) to be encapsulated, at least one polymer and at least one solvent containing or otherwise one surfactant, and then evaporating off the solvent.
- the surfactant optionally used in the preparation process can consist of at least one nonionic surfactant, more especially selected from the condensates of glycerol, ethylene oxide and propylene oxide, or of at least one ionic surfactant which can, in particular, be taken from the phospholipid group, such as lecithin, or alternatively of a mixture of at least one surfactant of each of these two categories.
- This surfactant promotes the formation of the microemulsion of oil, and prevents coalescence of the nanoparticles within the reaction mixture.
- the weight ratio of the surfactant used on the one hand, to the materials constituting the nanoparticles loaded with active ingredient(s) on the other hand is advantageously between 0.01 and 0.5, and preferably in the region of 0.2.
- a surfactant used during the process for manufacturing the nanoparticles When a surfactant used during the process for manufacturing the nanoparticles is in itself capable of forming vesicles consisting of lipid lamellae encapsulating a closed space, the said surfactant behaves in a fundamentally different way according to whether it is introduced into the aqeuous phase or into the solvent phase. If the surfactant is in the aqueous phase, it has a tendency, at least partially, to form vesicles. If, on the other hand, the surfactant is in the solvent phase, it has a tendency, at least partially, to form one or more lipid lamellae, each consisting of a molecular bilayer, around the polymer membrane of each nanoparticle.
- oil to be encapsulated is a self-emulsifying oil, selected, for example, from oxyethylenated triglycerides, it is not necessary to use a surfactant.
- the aqueous dispersion of nanoparticles obtained may be used as it is. It can also be lyophilized, in particular in the presence of anticaking additives such as silicas, sugars, salts, proteins, peptides and amino acids.
- the lyophilizates have the advantage of enabling anhydrous cosmetic compositions to be prepared. If the nanoparticles are coated with at least one lipid lamella consisting of at least one surfactant capable of forming vesicles, the compositions according to the invention can exhibit especially advantageous cosmetic features. These coated nanoparticles can constitute only a part of the nanoparticles of the composition.
- H denotes hour and D denotes day.
- Solubilisant S 12 is an emulsifier consisting of an oxyethylenated nonylphenol containing 12 moles of ethylene oxide, sold by the company “GIVAUDAN”.
- Solulan 16 is an emulsifier consisting of a mixture (lanolin alcohol/oxythylenated fatty alcohols containing 16 moles of ethylene oxide) sold by the company “AMERCHOL”.
- “Pluronic F 68” is a surfactant consisting of a condensate of ethylene oxide and propylene oxide, sold by the company “BASF”.
- “Kathon CG” is a preservative consisting of a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one and magnesium chloride and nitrate, sold by the company “ROHM and HAAS”.
- a placebo having the following composition was also prepared:
- the free radical-inhibiting effect of the aqueous dispersion of nanoparticles and of the placebo was then assessed in vivo in hairless mice by subjecting them to UV radiation and measuring the content of malonodialdehyde (MDA) in the skin, since MDA formation is induced by UV radiation.
- MDA malonodialdehyde
- mice are treated with a given number of applications of the test product. Each application is performed on the back of the mouse with 13.5 mg of preparation uniformly distributed over 4.5 cm 2 , and, when there are several applications, at 24-hour intervals.
- mice are subjected to UV radiation using an apparatus of the “BIOTRONIC UV 365/312 nm” type, which emits a spectrum with absorption peaks at 365 nm (for UV-A) provided by 2 40-W tubes and at 312 nm (for UV-B) provided by a 40-W tube.
- the irradiations are performed at doses of 4.00 J/cm 2 in UV-A and 4.00 J/cm 2 in UV-B.
- the mice are sacrificed and the irradiated skin is cut out.
- the application surface is wiped and a 100 mg fragment is introduced into 1.8 ml of phosphate buffer and then ground in an “ULTRA-TURRAX” for 1 min.
- the MDA is then assayed in a trichloroacetic acid medium and in the heated state by adding thiobarbituric acid, which combines with MDA to form a pink complex, and by measuring the concentration of this colored complex in a spectrophotometer.
- the radioactivity concentration of the dispersion is 120 ⁇ Ci/ml.
- a solution (not according to the invention, containing 1.5% by weight of radiolabelled ⁇ -tocopherol in silicone oil sold by the company “DOW CORNING” under the trade name “DC 200 FLUID” was prepared.
- the radioactivity concentration of the solution is 72 ⁇ Ci/ml.
- Skin biopsies were prepared from hairless female rats weighing 230-250 g. Identical amounts of labelled ⁇ -tocopherol, in encapsulated form in nanoparticles on the one hand, and in the form of a solution in silicone oil on the other hand, were applied to the surface of these biopsies on the stratum corneum side; they were left in contact for 24 hours. The dermis was then separated mechanically from the epidermis, and the ⁇ -tocopherol:
- the amount of ⁇ -tocopherol which has passed through the skin is significantly higher in the case of the solution in silicone oil than in the case of the dispersion of nanoparticles, but remains very small in both cases.
- the total amount of ⁇ -tocopherol retained in the skin is much higher in the case of the dispersion of nanoparticles than in the case of the solution in silicone oil, the majority of the ⁇ -tocopherol remaining in the epidermis in the case of the dispersion of nanoparticles.
- a colloidal dispersion of nanoparticles are recovered containing 5 g of encapsulated ⁇ -tocopherol, the diameter and the index of polydispersity (IP) of which, measured in a “nanosizer” (Coultronics particle size analyser), are 190 nm and 1, respectively.
- IP polydispersity
- the index IP is assessed on a scale from 0 to 9, 0 corresponding to a very homogeneous size dispersion whereas an index of 9 indicates a high ratio of the size of the largest particles to that of the smallest.
- Nanoparticles having an average diameter of 250 nm, with an index IP equal to 2, are obtained.
- Nanoparticles having an average diameter of 250 nm, with an index IP equal to 1, are obtained.
- Nanoparticles having an average diameter of 240 nm, with an index IP equal to 2, are obtained.
- the mixture is brought down to room temperature and 10 g of aqueous solution obtained by grinding animal placental tissues, sold by the company “GATTFEFOSSE” under the trade name “PHYLDERM”, and
- This physiological fluid is applied once a day to the cleansed skin of the face. After fifteen days' application, an effect of smoothing the skin of the face is observed.
- the mixture is homogenized and there are then added 20 g of water in which 0.05 g of crosslinked polyacrylic acid sold by the company “GOODRICH” under the trade name “CARBOPOL 1342” has been swollen.
- Example 6 After homogenization, 20 g of the aqueous dispersion of nanoparticles obtained in Example 6 are then added. 0.05 g of triethanolamine dissolved in 0.83 g of water is finally added. A green, very fluid moisturizing lotion having a pH equal to 6.7 is thereby obtained.
- This lotion is applied twice a day after cleansing the face, especially by individuals with dry skin. After one month's application, it is observed that the skin of the face is more supple, and that the sensation of tightness caused by the dryness of the skin is attenuated.
- This solution is homogenized by means of a scraper rotating at a speed of 30 rpm and an impeller rotating at 90 rpm, the preparation vessel being thermostated at a temperature of 20° C.
- an alcoholic solution composed of:
- the average diameter of the nanoparticles obtained is measured using a “BI 90” particle size analyzer (sold by the company “BROOKHAVEN”): it is 225 nm; the index of polydispersity is 2.
- This lotion is applied to the body every day after a shower or bath, especially during periods of frequent exposure to sunlight. It exerts a protective action on the skin against the harmful effects of solar radiation.
- an aqueous phase at the same temperature consisting of:
- Example 4 20 g of the aqueous dispersion of nanoparticles obtained in Example 4 is added with stirring provided by a “MORITZ” homogeniser.
- This cream is applied daily to a perfectly cleansed skin; it is intended, more especially, for skins exposed daily to solar radiation.
- this first mixture is dissolved in a second mixture consisting of:
- Liquid purcellin oil 3.00 g Product sold by the company “CRODA” under the 3.00 g trade name “Liquid base CB 1145” Isopropyl palmitate 4.75 g Liquid paraffin 7.9 g White vaseline 15 g Perhydrosqualene 0.4 g
- aqueous phase consisting of a mixture of a solution of 0.25 g of the mixture of preservatives sold by the company “LSN” under the trade name “ELESTAB 4110”, in 29.9 g of water, and 20 g of the aqueous dispersion of nano particles obtained in Example 5 is then introduced with stirring and at a temperature of 40° C.
- the product obtained is transferred to a triple-roller type mill.
- a thick, smooth white cream is thereby obtained, intended for the care of very dry and aged skins. After a twice-daily application of this cream for 15 days, an improvement of the surface condition of the treated skin is observed.
- Nanoparticles having an average diameter of 215 nm, with an index IP equal to 1, are obtained.
- Nanocapsules having an average diameter of 240 nm, with an index IP equal to 2, are obtained.
- n is an average statistical value equal to 6;
- R C 12 H 25 and R′ represents an equimolar mixture of tetradecyl and hexadecyl radicals
- These two lipids are homogenized by heating on a hotplate to a temperature of 100° C., and the mixture is then cooled to 40° C. 27.6 g of water in which 3 g of glycerol and 0.02 g of citric acid have been dissolved beforehand are then added. The whole is homogenized by the action of a “Virtis” type ultradisperser for 2 minutes at a speed of 40,000 rpm at a temperature of 40° C.
- macadamia oil 9 g volatile silicone oil 7 g ethylhexyl para-methoxycinnamate sold 0.5 g by the company “Givaudan” under the trade name “Parsol MCX” 2-hydroxy-4-methoxybenzophenone sold by 0.5 g the company “BASF” under the trade name “Uvinul M40” propyl para-hydroxybenzoate 0.05 g
- Example 4 20 g of the aqueous dispersion of nanoparticles obtained in Example 4 are then added. 35 g of water in which 0.65 g of vinylcarboxylic acid sold by the company “Goodrich” under the trade name “Carbopol 940” has been swollen are then added. After homogenization, 0.65 g of triethanolamine diluted with 1.73 g of water is finally added. A thick white cream of shiny appearance, intended for care of the face, is thereby obtained. After an application of this cream once a day for 15 days, an improvement in the surface condition of the treated skin is observed.
- aqueous-alcoholic gel consisting of soybean lecithin (20%), absolute ethanol (16 degrees alcohol strength) and water, marketed by the company “Natterman” under the trade name “Natipide II”,
- the whole is homogenized at room temperature using a “Virtis” ultradisperser for 3 minutes at a speed of 30,000 rpm. A dispersion of liposomes having an average size of 200 nm is thereby obtained.
- a beige physiological fluid is thereby obtained, which will be applied once a day to the cleansed skin of the face, before and after periods of exposure to sunlight. It is found that, despite the high frequency of exposure to sunlight and the duration of such periods of exposure, the skin shows no trace of irritation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Nanotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composition comprising biodegradable nanoparticles encapsulating oils which are active and/or which contain an active ingredient having a cosmetic and/or pharmaceutical action in the upper layers of the epidermis. The nanoparticles are preferably prepared from a polymer of (C2-C12) alkyl cyanoacrylate.
Description
This is a continuation of Application No. 07/961,537, filed Oct. 15, 1992, now abandoned which is a Rule 60 continuation of Ser. No. 07/668,308 filed Mar. 13, 1991, now abandoned.
The present invention relates to a composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis, by topical application of the said compositicn to the skin, and a preparation process for obtaining it.
It is well known in cosmetics and/or in pharmacy to apply to the skin oils which are active and/or which contain an active ingredient. These oils are used as they are or, more often, in the form of a water-in-oil or oil-in-water emulsion. These oils are known to have an action on the surface of the skin, but also in the upper layers of the epidermis, since they pass through the stratum corneum, the cosmetic and/or pharmaceutical action of the oils generally increasing in efficacy with an increase in the proportion of oil penetrating into the upper layers of the epidermis.
Moreover, nanoparticles are known: this name is used to denote colloidal particles of the order of 10 to 1,000 nm in size consisting of polymeric materials, in which an active principle is trapped, encapsulated and/or adsorbed (see J. KREUTER, J. MICROENCAPSULATION 1988, Vol. 5, pages 115-127). The term nanoparticles can be used to denote nanospheres and nanocapsules: a nanosphere constitutes a porous solid polymer matrix on which the active ingredient is adsorbed; a nanocapsule is a polymer membrane surrounding a core consisting of the active principle. For the remainder of the description and in the claims, the scope of the term “nanoparticles” will be strictly limited to nanocapsules defined above. Among polymers which may be used for the manufacture of nanoparticles, biodegradable materials are preferably selected in order to enable the said nanoparticles to be used therapeutically. It is known that cyanoacrylates, and especially polyalkyl cyanoacrylates, enable biodegradable nanoparticles to be obtained; the preparation of nanoparticles from cyanoacrylates is described in EP-B-0,007,895 and EP-B-0,064,967.
The use of biodegradable nanoparticles encapsulating biologically active compounds has been proposed in many therapeutic applications for many active principles, such as antimitotic or antineoplastic substances, antibiotics, hormonal substances, insulin, heparin or biological products such as proteins, antigens or the constituents of viruses, bacteria or cells. It has hence already been proposed to administer nanoparticles encapsulating active principles orally, subcutaneously, intradermally, intramuscularly, intravenously and by application to the eye (see EP-B-0,007,895, EP-B-0,064,967, FR-B-2,604,903, DE-A-3,722,837, DE-A-3,341,001 and FR-B-2,304,326).
In FR-A-2,515,960, nanoparticles of cyanoacrylate encapsulating an oil or an active substance dispersed in an oil have been described, and it is specified that these nanoparticles can be administered orally, subcutaneously, intradermally, intramuscularly or intravenously. In addition, in this document, the use of nanoparticles for encapsulating perfumes has been described, the encapsulated perfumes having the advantage of causing the perfume odor to persist longer after application than in the case where the perfume is applied to the skin without encapsulation; encapsulation hence has a delay action on the perfume. In addition, in this case, the desired action of the perfume takes place at the surface of the skin, and the persistence of the odor is completely independent of the fate of the fraction of the nanoparticles which might possibly pass through the stratum corneum. This topical application hence provides no information as to the possible capacity of the nanoparticles to pass through the stratum corneum and to be degraded in the upper layers of the epidermis; it leads, on the contrary, to the prediction that the nanoparticles would remain predominantly at the surface of the skin, since they permit release of the perfume.
According to the present application, it was found that, by cutaneous topical application of a composition comprising biodegradable nanoparticles encapsulating oils which are active and/or which contain an active ingredient, an especially effective cosmetic and/or pharmaceutical action was obtained.
The improvement in the cosmetic and/or pharmaceutical efficacy of the oils as a result of encapsulation in nanoparticles could in no way be foreseen; it was not obvious, in effect, on the one hand that the nanoparticles would pass through the stratum corneum more readily than the unencapsulated oil, whether the latter is in the form of a water-in-oil or oil-in-water emulsion, and on the other hand that these nanoparticles would be biodegraded in the upper layers of the epidermis. It was known, admittedly, that the proposed forms for administration in the human body, especially by injection, lead to biodegradation of the nanoparticles in the different tissue regions in which they are introduced. However, it is well known that different tissues have different constitutions and contain different enzymes; in particular, it is well known that the connective tissue of muscle, dermis and the deep layers of the skin, where the nanoparticles had previously been introduced by injection, have a very different biochemical constitution from that of the upper layers of the epidermis (see, for example, British Journal of Dermatology (1976) 94, 443).
Hence, nothing enabled those skilled in the art to anticipate that the nanoparticles were, on the one hand capable of passing through the stratum corneum in significant amounts, and on the other hand capable of releasing the active ingredient very rapidly into the upper layers of the epidermis.
According to the present invention, it was found, in addition, that the encapsulation of an active oil (or one containing an active ingredient) in nanoparticles produced, surprisingly, an immediate action of the composition. The delay effect reported for the perfuming compositions applied topically in the document FR-A-2,515,960 cited above led those skilled in the art to anticipate that a topical application, assuming it to be capable of having an effect, could have only a delayed action. The invention hence proposes a composition whose properties are unexpected. Moreover, these properties are especially well suited to topical administration, as was shown in a comparative in vitro study of percutaneous absorption.
The subject of the present invention is consequently a composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis, by topical application to the skin, characterised in that it comprises, in a suitable vehicle, biodegradable polymer nanoparticles encapsulating at least one active ingredient in the form of an oil and/or at least one active ingredient contained in an inactive carrier oil or an active oil, the active ingredient being selected from those having a cosmetic and/or pharmaceutical action.
The nanoparticles used are preferably between 10 and 1000 nm, and more especially between 50 and 500 nm, in size.
The weight of the nanoparticles loaded with at least one active ingredient advantageously constitutes from 0.1% to 20% of the total weight of the composition, and preferably from 0.5 to 5%. by weight.
The polymers constituting the biodegradable nanoparticles can be polymers of C2-C12, and especially C2-C6, alkyl cyanoacrylate; the alkyl radical is preferably selected from the group composed of ethyl, n-butyl, hexyl, isobutyl and isohexyl radicals. The biodegradable polymers may also be taken from the group composed of poly-L-lactides, poly-DL-lactides, polyglycolides, polycaprolactones, polymers of 3-hydroxybutyric acid and the corresponding copolymers, such as copoly(DL-lactides/glycolides), copoly(glycolides/caprocolatones) and the like.
The use of nanoparticles obtained from poly-L-lactides, poly-DL-lactides and copoly(DL-lactides/glycolides) is especially advantageous, since the products of enzymatic or chemical biodegradation of these nanoparticles can themselves have cosmetic effects: thus, lactic acid exhibits humectant and plasticising properties; and glycolic acid exhibits depigmenting and/or biostimulatory properties.
The active ingredients in the form of an oil (or active oils) are preferably selected from the group composed of α-tocopherol, α-tocopherol acetate, triglycerides rich in linoleic and/or linolenic acid(s), pentaerythritol tetra(2-ethylhexanoate), clofibrate, tocopherol linoleate, fish oil, hazelnut oil, bisabolol, farnesol, farnesyl acetate, ethyl linoleate and ethylhexyl para-methoxycinnamate.
The inactive carrier oils are preferably selected from the group composed of triglycerides, simple or modified, especially by oxyethylenation, volatile silicone oils and mixtures thereof.
To obtain the loaded nanoparticles used in the composition according to the invention it is possible either to take an active oil, or to introduce into an active oil or into a carrier oil which is in itself inactive, any active ingredient capable of having a cosmetic or therapeutic activity. These active ingredients can be, inter alia, emollients, humectants, free radical-inhibiting agents, anti-inflammatories, vitamins, depigmenting agents, anti-acne agents, antiseborrhoeics, keratolytics, slimming agents, skin coloring agents and sunscreen agents, and in particular linoleic acid, retinol, retinoic acid, ascorbic acid alkyl esters, polyunsaturated fatty acids, nicotinic esters, tocopherol nicotinate, unsaponifiables of rice, soybean or shea, ceramides, hydroxy acids such as glycolic acid, selenium derivatives, antioxidants, β-carotene, γ-orizanol and stearyl glycerate.
The active ingredient is preferably an oleophilic active ingredient in the form of a solution in the oil. However, it can also be in the form of a dispersion, suspension or emulsion.
In the nanoparticles, the weight ratio of the biodegradable polymer of the nanoparticles to the active oily phase is preferably between 0.05 and 0.5, and in particular in the region of 0.2.
The compositions according to the invention can take the form of a physiological fluid, a lotion, an aqueous, aqueous-alcoholic or oily gel or a water-in-oil or oil-in-water emulsion, or alternatively of aqueous dispersions of vesicles in which the constituent lipids are ionic or nonionic lipids or a mixture of ionic and nonionic lipids, with or without an oily phase. Their use to constitute physiological fluids is especially advantageous: in effect, this type of product requires the introduction of a large amount of emulsifier in the case where it is desired to introduce unencapsulated oily active ingredients into them, and it is well known that emulsifiers have the effect of irritating the skin and are not compatible with all active ingredients.
The compositions can contain, in addition to the nanoparticles, known cosmetically and/or pharmaceutically acceptable adjuvants, such as fats, vaseline, preservatives, thickening agents, colorings and perfumes.
When a polymer of (C2-C12) alkyl cyanoacrylate is used to obtain the nanoparticles of the composition, an interfacial polymerisation of a microemulsion of oil in an aqeuous-alcoholic medium is performed, as described, for example, in FR-A-2,515,960, by injecting, into an aqeuous phase containing or otherwise one surfactant, a mixture consisting of the oil(s) to be encapsulated, at least one (C2-C12) alkyl cyanoacrylate and at least one solvent which can contain one surfactant, then evaporating off the solvent and optionally concentrating the aqueous dispersion of nanoparticles obtained. The solvent used is, more often than not, a C2-C4 lower alcohol, especially ethanol, propanol, isopropanol or a mixture of these alcohols, or alternatively acetone; it can optionally contain one surfactant.
It is also possible to use the process for manufacturing nanoparticles described in European Patent Application No. 0,274,961. In this case, the nanoparticles are obtained by precipitation of the polymer around a dispersion of oily droplets, by injecting, into an aqueous phase containing or otherwise one surfactant, a mixture consisting of the oil(s) to be encapsulated, at least one polymer and at least one solvent containing or otherwise one surfactant, and then evaporating off the solvent.
Other processes may also be used.
The surfactant optionally used in the preparation process can consist of at least one nonionic surfactant, more especially selected from the condensates of glycerol, ethylene oxide and propylene oxide, or of at least one ionic surfactant which can, in particular, be taken from the phospholipid group, such as lecithin, or alternatively of a mixture of at least one surfactant of each of these two categories. This surfactant promotes the formation of the microemulsion of oil, and prevents coalescence of the nanoparticles within the reaction mixture. The weight ratio of the surfactant used on the one hand, to the materials constituting the nanoparticles loaded with active ingredient(s) on the other hand, is advantageously between 0.01 and 0.5, and preferably in the region of 0.2.
When a surfactant used during the process for manufacturing the nanoparticles is in itself capable of forming vesicles consisting of lipid lamellae encapsulating a closed space, the said surfactant behaves in a fundamentally different way according to whether it is introduced into the aqeuous phase or into the solvent phase. If the surfactant is in the aqueous phase, it has a tendency, at least partially, to form vesicles. If, on the other hand, the surfactant is in the solvent phase, it has a tendency, at least partially, to form one or more lipid lamellae, each consisting of a molecular bilayer, around the polymer membrane of each nanoparticle.
In the case where the oil to be encapsulated is a self-emulsifying oil, selected, for example, from oxyethylenated triglycerides, it is not necessary to use a surfactant.
The aqueous dispersion of nanoparticles obtained may be used as it is. It can also be lyophilized, in particular in the presence of anticaking additives such as silicas, sugars, salts, proteins, peptides and amino acids. The lyophilizates have the advantage of enabling anhydrous cosmetic compositions to be prepared. If the nanoparticles are coated with at least one lipid lamella consisting of at least one surfactant capable of forming vesicles, the compositions according to the invention can exhibit especially advantageous cosmetic features. These coated nanoparticles can constitute only a part of the nanoparticles of the composition.
The examples given below, purely by way of illustration and without implied limitation, will facilitate understanding of the invention.
In this example, for the purpose of comparison, an aqeuous dispersion of nanoparticles of polymer of butyl cyanoacrylate containing α-tocopherol, prepared according to the procedure of Example 3, in an aqueous phase containing a surfactant and ethanol, and two emulsions of α-tocopherol in water obtained using two different emulsifiers, were studied. Skin irritation (SIR) and eye irritation (EI) were then measured.
The SIR measurements were performed according to the protocol described in the Ministerial Decree of Feb. 1, 1982, published in the Journal Officiel de la République Française (J.O.R.F) (Official Journal of the French Republic) dated Feb. 21, 1982.
The EI measurements were performed according to the protocol described in the Ministerial Decree of Sep. 21, 1984, published in the J.O.R.F. of Oct. 24, 1984 and Feb. 9, 1985.
The compositions and results are given in Table I.
TABLE I | |||
Emulsion No. 1 | Emulsion No. 2 | ||
Nanoparticles | not according | not according | |
Composition | according to | to the | to the |
in % | the invention | invention | invention |
α-Tocopherol | 1.0 | 1.0 | 1.0 |
Butyl cyano- | |||
acrylate | 0.2 | — | — |
Solubilisant S 12 | — | 2.0 | — |
Solulan 16 | — | — | 2.0 |
Pluronic F 68 | 0.2 | — | — |
Kathon CG | 0.1 | 0.1 | 0.1 |
Water | qs 100 | qs 100 | qs 100 |
Nature of the |
measurement | Results |
SIR | 0.08 | 0.29 | 2.0 |
EI | 2.6 at 1 H | 11.83 at 1 H | 5.67 at 1 H |
″ | 1.0 at 1 D | 1.67 at 1 D | 2.33 at 1 D |
″ | 0.0 at 2 D | 0.67 at 2 D | 1.33 at 2 D |
″ | 0.0 at 3 D | 0.0 at 3 D | |
In this Table I:
H denotes hour and D denotes day.
“Solubilisant S 12” is an emulsifier consisting of an oxyethylenated nonylphenol containing 12 moles of ethylene oxide, sold by the company “GIVAUDAN”.
“Solulan 16” is an emulsifier consisting of a mixture (lanolin alcohol/oxythylenated fatty alcohols containing 16 moles of ethylene oxide) sold by the company “AMERCHOL”.
“Pluronic F 68” is a surfactant consisting of a condensate of ethylene oxide and propylene oxide, sold by the company “BASF”.
“Kathon CG” is a preservative consisting of a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one and magnesium chloride and nitrate, sold by the company “ROHM and HAAS”.
According to this table, it is seen that, to obtain the emulsions 1 and 2, 2% of emulsifier was needed in order to microdisperse 1% of α-tocopherol. On the other hand, it is seen that the composition based on nanoparticles proves distinctly less irritant to the skin than the two emulsions, and that eye irritation (EI) is also reduced, both after one hour and after two days.
In this further comparative example, an aqueous dispersion of nanoparticles according to the invention, having the following weight composition, was prepared according to the procedure of Example 4:
α-Tocopherol | 5% | ||
Butyl cyanoacrylate | 1% | ||
Surfactant sold by the company “ICI” | 1% | ||
under the trade name “SYMPERONIC PE/F68” | |||
Preservative sold by the company | 0.1% | ||
“ROHM and HAAS” under the trade name | |||
“KATHON CG” | |||
Water | 92.9% | ||
A placebo having the following composition was also prepared:
Oil sold by the company “DYNAMIT NOBEL” | 5% | ||
under the trade name “MIGLYOL 812” | |||
Butyl cyanoacrylate | 1% | ||
Surfactant sold by the company “ICI” | 1% | ||
under the trade name “SYMPERONIC PE/F68” | |||
Preservative sold by the company | 0.1% | ||
“ROHM and HAAS” under the trade name | |||
“KATHON CG” | |||
Water | 92.9% | ||
The free radical-inhibiting effect of the aqueous dispersion of nanoparticles and of the placebo was then assessed in vivo in hairless mice by subjecting them to UV radiation and measuring the content of malonodialdehyde (MDA) in the skin, since MDA formation is induced by UV radiation.
The mice are treated with a given number of applications of the test product. Each application is performed on the back of the mouse with 13.5 mg of preparation uniformly distributed over 4.5 cm2, and, when there are several applications, at 24-hour intervals.
One hour after the final application, the mice are subjected to UV radiation using an apparatus of the “BIOTRONIC UV 365/312 nm” type, which emits a spectrum with absorption peaks at 365 nm (for UV-A) provided by 2 40-W tubes and at 312 nm (for UV-B) provided by a 40-W tube. The irradiations are performed at doses of 4.00 J/cm2 in UV-A and 4.00 J/cm2 in UV-B. Three hours after completion of the irradiation, the mice are sacrificed and the irradiated skin is cut out. After several washes, the application surface is wiped and a 100 mg fragment is introduced into 1.8 ml of phosphate buffer and then ground in an “ULTRA-TURRAX” for 1 min. The MDA is then assayed in a trichloroacetic acid medium and in the heated state by adding thiobarbituric acid, which combines with MDA to form a pink complex, and by measuring the concentration of this colored complex in a spectrophotometer.
The results are given in Table II:
TABLE II | ||
MDA content (MEAN + | ||
SEM) in | ||
Number of applications | nanomoles MDA/mg | |
Test | before irradiation | protein |
Unirradiated | 0 | 2.655 ± 0.048 |
control | ||
Irradiated | 0 | 3.780 ± 0.277 |
control | ||
Nanoparticles | 1 | 2.651 ± 0.199 |
″ | 4 | 2.461 ± 0.255 |
Placebo | 1 | 4.190 ± 0.323 |
″ | 4 | 3.800 ± 0.326 |
It is seen in this table that the effect of the active ingredient encapsulated in the nanoparticles is maximal from the first application onwards, and hence immediate.
In this third comparative example, a dispersion of nanoparticles according to the invention, having the following weight composition, was prepared according to the procedure of Example 4:
Surfactant sold by the company “BASF” | 0.6% | ||
under the trade name “PLURONIC F 68” | |||
Preservative sold by the company “ROHM & | 0.05% | ||
HAAS” under the trade name “KATHON CG” | |||
Butyl cyanoacrylate | 0.3% | ||
α-Tocopherol, radiolabelled | 1.5% | ||
Water q.s. | 100% | ||
The radioactivity concentration of the dispersion is 120 μCi/ml.
Furthermore, a solution (not according to the invention, containing 1.5% by weight of radiolabelled α-tocopherol in silicone oil sold by the company “DOW CORNING” under the trade name “DC 200 FLUID” was prepared. The radioactivity concentration of the solution is 72 μCi/ml.
The penetration of the α-tocopherol in the dispersion of nanoparticles and in the solution in silicone oil into the different layers of the skin was then assessed. The study was performed in vitro with Franz cells, cells described in “The Journal of Investigative Dermatology, volume 64 (1975), pages 190-195”.
Skin biopsies were prepared from hairless female rats weighing 230-250 g. Identical amounts of labelled α-tocopherol, in encapsulated form in nanoparticles on the one hand, and in the form of a solution in silicone oil on the other hand, were applied to the surface of these biopsies on the stratum corneum side; they were left in contact for 24 hours. The dermis was then separated mechanically from the epidermis, and the α-tocopherol:
which had passed through the skin | A | ||
found in the skin | |||
in the epidermis | B | ||
and in the dermis | C | ||
which had not penetrated into the skin | D | ||
was assayed.
The results obtained are collated in Table III below, where they are given in percentages by weight of α-tocopherol for 100% of α-tocopherol applied.
TABLE III | |||
α-tocopherol (% by weight) |
Test | A | B | C | D | ||
Silicone oil | 0.73 | 25.6 | 24.3 | 54.4 | ||
Nanoparticles | 0.42 | 63.8 | 17.9 | 16.7 | ||
In this table, it may be observed that the amount of α-tocopherol which has passed through the skin is significantly higher in the case of the solution in silicone oil than in the case of the dispersion of nanoparticles, but remains very small in both cases. Moreover, the total amount of α-tocopherol retained in the skin (epidermis and dermis) is much higher in the case of the dispersion of nanoparticles than in the case of the solution in silicone oil, the majority of the α-tocopherol remaining in the epidermis in the case of the dispersion of nanoparticles.
In a 1250-ml beaker, 1 g of a mixture of condensates of ethylene oxide and propylene oxide (20%/80% by weight), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “PLURONIC F-68), is dissolved in 500 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm.
620 ml of absolute ethanol in which the following have been dissolved beforehand:
5 g of α-tocopherol, and
1 g of n-butyl cyanoacrylate
are poured slowly dropwise into this aqueous phase.
Stirring is maintained for two hours while the temperature of the reaction medium is adjusted to 20° C. using a thermostated bath. After these two hours, the dispersion of nanoparticles obtained is transferred to a 1-liter round-bottomed flask which is placed on a rotary evaporator, and the ethanol and a part of the water are evaporated off.
95 g of a colloidal dispersion of nanoparticles are recovered containing 5 g of encapsulated α-tocopherol, the diameter and the index of polydispersity (IP) of which, measured in a “nanosizer” (Coultronics particle size analyser), are 190 nm and 1, respectively.
The index IP is assessed on a scale from 0 to 9, 0 corresponding to a very homogeneous size dispersion whereas an index of 9 indicates a high ratio of the size of the largest particles to that of the smallest.
5 g of an aqueous solution containing 0.1 g of a preservative sold by the company “ROHM & HAAS” under the trade name “KATHON CG” are finally added.
An aqueous dispersion having the following composition was prepared according to the same procedure as in Example 4:
Condensates of ethylene oxide and propylene | 0.4 | g | ||
oxide, sold by the company “BASF” under the | ||||
trade name “PLURONIC F-68” | ||||
Safflower oil | 1.0 | g | ||
Isohexyl cyanoacrylate | 0.4 | g | ||
Water q.s. | 100 | g | ||
Nanoparticles having an average diameter of 250 nm, with an index IP equal to 2, are obtained.
An aqueous dispersion having the following composition was prepared according to the same procedure as in Example 4:
Condensates of ethylene oxide and propylene | 0.2 | g | ||
oxide, sold by the company “BASF” under the | ||||
trade name “PLURONIC F-68” | ||||
Pentaerythritol tetra(2-ethylhexanoate) | 1.0 | g | ||
Butyl cyanoacrylate | 0.2 | g | ||
Water q.s. | 100 | g | ||
Nanoparticles having an average diameter of 250 nm, with an index IP equal to 1, are obtained.
An aqueous dispersion having the following composition was prepared according to the same procedure as in Example 4:
Condensates of ethylene oxide and propylene | 0.4 | g | ||
oxide, sold by the company “BASF” under the | ||||
trade name “PLURONIC F-68” | ||||
Triglycerides sold by the company “DYNAMIT | 1.0 | g | ||
NOBEL” under the trade name “MIGLYOL 812” | ||||
Vitamin A palmitate | 0.02 | g | ||
Butyl cyanoacrylate | 0.2 | g | ||
Water q.s. | 100 | g | ||
Nanoparticles having an average diameter of 240 nm, with an index IP equal to 2, are obtained.
In a 200-ml beaker, 0.3 g of crosslinked polyacrylic acid, sold by the company “GOODRICH” under the trade name “CARBOPOL 940”, is swollen in 41.1 g of water containing 0.1 g of methyl para-hydroxybenzoate dissolved beforehand. This operation is carried out at a temperature of 80° C.; the mixture is then gradually brought down to a temperature of 40° C. 5 g of water containing 0.1 g of natural gum sold by the company “SATIA” under the trade name “AUBY GUM X2” are added.
After homogenization, the mixture is brought down to room temperature and 10 g of aqueous solution obtained by grinding animal placental tissues, sold by the company “GATTFEFOSSE” under the trade name “PHYLDERM”, and
2 g of glycerol,
1 g of hexylene glycol,
15 g of rose water
are added.
After homogenization, 0.1 g of the preservative sold by the company “DOW CHEMICAL” under the trade name “DOWICIL 200”, dissolved beforehand in 5 g of water, is added. 10 g of the aqueous dispersion of nanoparticles prepared in Example 4 and 10 g of the aqueous dispersion of nanoparticles prepared according to Example 7 are added. After homogenization, 0.3 g of triethanolamine is added. A bluish-white physiological fluid having a viscosity equal to 1.6 poises and a pH equal to 7 is thereby obtained.
This physiological fluid is applied once a day to the cleansed skin of the face. After fifteen days' application, an effect of smoothing the skin of the face is observed.
In a 200-ml beaker, the following are dissolved in 25 g of rose water:
0.25 mg of dye “FD and C BLUE 1” marketed by the company “ALLIED CHEMICAL”; and
0.1 g of dye “D and C YELLOW 10” marketed by the company “ANSTEAD”.
30.2 g of water containing 0.9 g of sodium chloride are then added, followed by 1.0 g of butylene glycol and 2.0 g of glycerol.
The mixture is homogenized and there are then added 20 g of water in which 0.05 g of crosslinked polyacrylic acid sold by the company “GOODRICH” under the trade name “CARBOPOL 1342” has been swollen.
After homogenization, 20 g of the aqueous dispersion of nanoparticles obtained in Example 6 are then added. 0.05 g of triethanolamine dissolved in 0.83 g of water is finally added. A green, very fluid moisturizing lotion having a pH equal to 6.7 is thereby obtained.
This lotion is applied twice a day after cleansing the face, especially by individuals with dry skin. After one month's application, it is observed that the skin of the face is more supple, and that the sensation of tightness caused by the dryness of the skin is attenuated.
380.50 g of floral water in which the following are dissolved:
0.5 g of hamamelis essence in a glycol carrier, marketed by the company “SOSHIBO”,
2.5 g of hexylene glycol,
10.0 g of glycerol, and
1.0 g of condensates of ethylene oxide and propylene oxide, sold by the company “BASF” under the trade name “PLURONIC F-68” are poured into the 1-liter glass vessel of a “COS 1000” homogenizer marketed by the company “COSMETOCHEM”.
This solution is homogenized by means of a scraper rotating at a speed of 30 rpm and an impeller rotating at 90 rpm, the preparation vessel being thermostated at a temperature of 20° C. During this homogenisation, an alcoholic solution composed of:
ethanol | 75 | g | ||
butyl cyanoacrylate | 0.5 | g | ||
α-tocopherol acetate | 5.0 | g | ||
is added in continuous fashion in the course of 20 minutes.
After complete introduction of the alcohol phase, the speed of the impeller is reduced to 70 rpm and this stirring is maintained for two hours.
24.25 g of water containing the following preservatives in the dissolved state are then added:
Preservative sold by the Company “DOW CHEMICAL” | 0.5 | g | ||
under the trade name “DOWICIL 200” | ||||
Preservative sold by the Company “ROHM & | 0.25 | g | ||
HAAS” under the trade name “KATHON CG” | ||||
500 g of an alcoholic lotion are thereby obtained. The average diameter of the nanoparticles obtained is measured using a “BI 90” particle size analyzer (sold by the company “BROOKHAVEN”): it is 225 nm; the index of polydispersity is 2.
This lotion is applied to the body every day after a shower or bath, especially during periods of frequent exposure to sunlight. It exerts a protective action on the skin against the harmful effects of solar radiation.
In a 200-ml glass beaker, the following are dissolved in 24 g of liquid paraffin heated to a temperature of 65° C.:
5 g of cetyl alcohol, and
3 g of a polyethylene glycol monostearate containing 50 moles of ethylene oxide, sold by the company “ICI” under the trade name “MYRJ 53”.
After the mixture has been brought down to a temperature of 50° C., an aqueous phase at the same temperature consisting of:
a solution in 44.7 g of water of 0.3 g of the mixture of preservatives sold by the company “LSN” under the trade name “ELESTAB 4112”, and
20 g of the aqueous dispersion of nanoparticles obtained in Example 4 is added with stirring provided by a “MORITZ” homogeniser.
Homogenization is maintained during cooling of the product to room temperature. 100 g of a thick white cream which has a protective effect against solar radiation are thereby obtained.
This cream is applied daily to a perfectly cleansed skin; it is intended, more especially, for skins exposed daily to solar radiation.
In a 200-ml glass beaker, the following compounds are mixed at a temperature of 85° C. using a “MORITZ” homogeniser:
Product sold by the company “CHIXEX” under the | 5.70 | g | ||
trade name “MEXANYL GO” | ||||
Hydrogenated lanolin sold by the company | 6.65 | g | ||
“RITA” under the tradename “SUPERSAT” | ||||
Product manufactured by the company | 2.00 | g | ||
“CHIMEX”, sold under the trade name | ||||
“MEXANYL GP” | ||||
After homogenisation, this first mixture is dissolved in a second mixture consisting of:
Liquid purcellin oil | 3.00 | g | ||
Product sold by the company “CRODA” under the | 3.00 | g | ||
trade name “Liquid base CB 1145” | ||||
Isopropyl palmitate | 4.75 | g | ||
Liquid paraffin | 7.9 | g | ||
White vaseline | 15 | g | ||
Perhydrosqualene | 0.4 | g | ||
These two mixtures are homogenized at a temperature of 80° C. and then cooled to a temperature of 40° C. 0.8 g of perfume sold by the company “FIRMENICH” under the trade name “CHEMODERM 1008” is then added.
An aqueous phase consisting of a mixture of a solution of 0.25 g of the mixture of preservatives sold by the company “LSN” under the trade name “ELESTAB 4110”, in 29.9 g of water, and 20 g of the aqueous dispersion of nano particles obtained in Example 5 is then introduced with stirring and at a temperature of 40° C.
This stirring is maintained for 20 minutes, and 0.3 g of preservative sold by the company “ROHM & HAAS” under the trade name “GERMAL 115”, treated with 0.35 g of water, is then added.
After return of the mixture to room temperature, the product obtained is transferred to a triple-roller type mill.
A thick, smooth white cream is thereby obtained, intended for the care of very dry and aged skins. After a twice-daily application of this cream for 15 days, an improvement of the surface condition of the treated skin is observed.
An aqueous dispersion having the following composition is prepared according to the same procedure as in Example 4:
Condensate of ethylene oxide and propylene | 0.25 | g | ||
oxide, sold by the company “BASF” under the trade | ||||
name “Pluronic F 68” | ||||
Bisabolol | 0.5 | g | ||
α-Tocopherol acetate | 0.5 | g | ||
Butyl cyanoacrylate | 0.2 | g | ||
Water q.s. | 100 | g | ||
Nanoparticles having an average diameter of 215 nm, with an index IP equal to 1, are obtained.
An aqueous dispersion having the following composition was prepared according to the same procedure as in Example 4:
Condensate of ethylene oxide and propylene | 0.25 | g | ||
oxide, sold by the company “BASF” under the trade | ||||
name “Pluronic F 68” | ||||
Mixture of decyl oleate, farnesol, ethyl | 1.0 | g | ||
linoleate and farnesyl acetate, sold by | ||||
the company “Induchem” under the trade | ||||
name “Unibiovit B 33” | ||||
Butyl cyanoacrylate | 0.2 | g | ||
Water q.s. | 100 | g | ||
Nanocapsules having an average diameter of 240 nm, with an index IP equal to 2, are obtained.
1) Preparation of the Dispersion of Vesicles
in which:
n is an average statistical value equal to 6;
R=C12H25 and R′ represents an equimolar mixture of tetradecyl and hexadecyl radicals,
are weighed into a 100-ml glass beaker.
These two lipids are homogenized by heating on a hotplate to a temperature of 100° C., and the mixture is then cooled to 40° C. 27.6 g of water in which 3 g of glycerol and 0.02 g of citric acid have been dissolved beforehand are then added. The whole is homogenized by the action of a “Virtis” type ultradisperser for 2 minutes at a speed of 40,000 rpm at a temperature of 40° C. There are then added 3 g of water in which 0.1 g of preservative sold by the company “Rohm and Haas” under the trade name “Kathon CG” and 0.2 g of preservative sold by the company “Rohm and Haas” under the trade name “Germal 115” have been dissolved beforehand.
The fatty phase composed of the following mixture of products is then added:
macadamia oil | 9 | g | ||
volatile silicone oil | 7 | g | ||
ethylhexyl para-methoxycinnamate sold | 0.5 | g | ||
by the company “Givaudan” under the trade | ||||
name “Parsol MCX” | ||||
2-hydroxy-4-methoxybenzophenone sold by | 0.5 | g | ||
the company “BASF” under the trade name | ||||
“Uvinul M40” | ||||
propyl para-hydroxybenzoate | 0.05 | g | ||
The whole is subjected to the action of a “Virtis” ultradisperser for 5 minutes at room temperature.
2) Mixing of the dispersions of Vesicles and Nanoparticles
20 g of the aqueous dispersion of nanoparticles obtained in Example 4 are then added. 35 g of water in which 0.65 g of vinylcarboxylic acid sold by the company “Goodrich” under the trade name “Carbopol 940” has been swollen are then added. After homogenization, 0.65 g of triethanolamine diluted with 1.73 g of water is finally added. A thick white cream of shiny appearance, intended for care of the face, is thereby obtained. After an application of this cream once a day for 15 days, an improvement in the surface condition of the treated skin is observed.
In a 100-ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase thermostated at a temperature of 40° C., 25 ml of acetone in which the following have been dissolved beforehand at a temperature of 40° C.:
125 mg of DL-polylactic acid sold by the company “Polysciences”
500 mg of α-tocopherol acetate sold by the company “Roche”, and
2 mg of “Nile Red” dye (Nile Blue A Oxazone) sold by the company “Sigma”,
are poured slowly.
Stirring is maintained for 2 hours at a temperature of 40° C. and the mixture is then brought down to room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid colloidal dispersion of nanoparticles having an average diameter of 295 nm, with an index IP equal to 2, is thereby obtained.
On microscopic examination under fluorescence conditions, a dense population of nanoparticles fluorescent to the core, with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanoparticles is observed on examination under fluorescence conditions, nor are large variations observed in their size (in all cases, the variations are less than 10% of the initial average diameter).
In a 100-ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase thermostated at a temperature of 40° C., 25 ml of acetone in which 125 mg of soybean lecithin, sold by the company “Lucas Meyer” under the trade name “Epikuron 170” have been dissolved beforehand at a temperature of 55° C. are poured slowly; then, after the mixture has been brought down to a temperature of 40° C., the following are dissolved:
125 mg of DL-polylactic acid sold by the company “Polysciences”,
500 mg of α-tocopherol acetate sold by the company “Roche”, and
2 mg of “Nile Red” dye (Nile Blue A Oxazone) sold by the company “Sigma”.
Stirring is maintained for 2 hours at a temperature of 40° C. and the mixture is then brought down to room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid white colloidal dispersion of nanoparticles having an average diameter of 225 nm, with an index IP equal to 2, is thereby obtained.
On microscopic examination under fluorescence conditions, a dense population of nanoparticles fluorescent to the core, with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement, is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanoparticles is observed on examination by fluorescence microscopy, nor are large variations observed in their size (in all cases, the variations are less than 10% of the initial average diameter).
In a 100-ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase thermostated at a temperature of 40° C., 25 ml of acetone in which the following have been dissolved beforehand at a temperature on 40° C.
125 mg of DL-polylactic acid sold by the company “Polysciences”, and
500 mg of α-tocopherol acetate sold by the company “Roche”
are poured slowly.
Stirring is maintained for 2 hours at a temperature of 40° C. and the mixture is then brought down to room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid white colloidal dispersion of nanoparticles having an average diameter of 310 nm, with an index IP equal to 2, is thereby obtained.
On microscopic examination, a dense population of nanoparticles with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement, is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanocapsules is observed, nor are large variations observed in their size (in all cases, the variations are less than 10% of the initial average diameter).
In a 100-ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase thermostated at a temperature of 40° C., 25 ml of acetone in which 250 mg of soybean lecithin, sold by the company “Lucas Meyer” under the trade name “Epikuron 170”, have been dissolved beforehand at a temperature of 55° C. are poured slowly; then, after the mixture has been brought down to a temperature of 40° C., the following are dissolved:
125 mg of DL-polylactic acid sold by the company “Polysciences”, and
500 mg of ethylhexyl para-methoxycinnamate marketed by the company “Givaudan” under the trade name “Parsol MCX”.
Stirring is maintained for 2 hours at a temperature of 40° C. and the mixture is then brought down to room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid white colloidal dispersion of nanoparticles having an average diameter of 240 rnm, with an index IP equal to 2, is thereby obtained.
On microscopic examination in white light, a dense population of nanoparticles with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement, is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanoparticles is observed on microscopic examination, nor are large variations observed in their size (in all cases, the variations are less than 10% of the initial average diameter).
In a 100-ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase, 25 ml of acetone, in which 500 mg of α-tocopherol acetate and 125 mg of polymer of butyl cyanoacrylate obtained by prior self-polymerization in water of butyl cyanoacrylate monomer, isolation by centrifugation and then drying by lyophilization has been dissolved beforehand, are poured slowly. Stirring is maintained for 2 hours at room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid colloidal dispersion of nanoparticles having an average diameter of 220 nm, with an index IP equal to 1, is thereby obtained.
On microscopic examination under fluorescence conditions, a dense population of nanoparticles fluorescent to the core, with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement, is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanoparticles is observed on examination under fluorescence conditions, nor are large variations observed in their size (in all cases, the variations are less than 10% of the initial average diameter).
In a 100-ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the company “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase thermostated at a temperature of 40° C., 25 ml of acetone in which 250 mg of soybean lecithin, sold by the company “Lucas Meyer” under the trade name “Epikuron 170”, have been dissolved beforehand at a temperature of 55° C. are poured slowly; then, after the mixture has been brought down to a temperature of 40° C., the following are dissolved:
500 mg of α-tocopherol acetate marketed by the company “Roche”, and
125 mg of copoly(DL-lactide/glycolide) (in the mole ratio 50:50) marketed by the company “Dupont de Nemours” under the trade name “Medisorb T.M.”.
Stirring is maintained for 2 hours at a temperature of 40° C. and the mixture is then brought down to room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid colloidal dispersion of nanoparticles having an average diameter of 210 nm, with an index IP equal to 1, is thereby obtained.
On microscopic examination under fluorescence conditions, a dense population of nanoparticles fluorescent to the core, with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement, is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanoparticles is observed on examination under fluorescence conditions, nor are large variations obsreved in their size (in all cases, the variations are less than 10% of the initial average diameter).
In a 100 ml beaker, 250 mg of condensate of ethylene oxide and propylene oxide (20/80%), of average molecular weights 1750 and 8350, respectively, sold by the cqmpany “BASF” under the trade name “Pluronic F68”, are dissolved in 50 ml of demineralized water with stirring provided by a bar magnet rotating at 400 rpm. Into this aqueous phase thermostated at a temperature of 40° C., 25 ml of acetone in which 250 mg of soybean lecithin, sold by the company “Lucas Meyer” under the trade name “Epikuron 170”, have been dissolved beforehand at a temperature of 55° C. are poured slowly; then, after the mixture has been brought down to a temperature of 40° C., the following are dissolved:
500 mg of α-tocopherol acetate marketed by the company “Roche”, and
125 mg of polycaprolactone marketed by the company “Aldrich”.
Stirring is maintained for 2 hours at a temperature of 40° C. and the the mixture is then brought down to room temperature. The dispersion of nanoparticles obtained is then transferred to a 250-ml round-bottomed flask which is placed on a rotary evaporator, and the acetone is evaporated off. A fluid colloidal dispersion of nanoparticles having an average diameter of 195 nm, with an index IP equal to 2, is thereby obtained.
On microscopic examination in white light, a dense population of nanoparticles with a clearly distinctive identity, homogeneous in size and agitated in Brownian movement, is observed. After 2 months' storage at temperatures of +4, 25, 37 and 45° C., no modification of the appearance of the nanoparticles is observed on examination under fluorecence conditions, nor are large variations observed in their size (in all cases, the variations are less than 10% of the initial average diameter).
The following are weighed into a 200-ml fluted glass vessel:
2.5 g of an aqueous-alcoholic gel consisting of soybean lecithin (20%), absolute ethanol (16 degrees alcohol strength) and water, marketed by the company “Natterman” under the trade name “Natipide II”,
0.01 g of ascorbyl palmitate,
5.0 g of glycerol, and
17.5 g of water.
The whole is homogenized at room temperature using a “Virtis” ultradisperser for 3 minutes at a speed of 30,000 rpm. A dispersion of liposomes having an average size of 200 nm is thereby obtained.
1 g of polyethylene glycol 400 and 3.0 g of propylene glycol are then added: the whole is mixed at room temperature for 1 minute with the “Virtis” ultradisperser. 10 g of aqueous solution obtained by grinding animal placental tissues, sold by the company “Gattefossé” under the trade name “Phylderm”, are added: the whole is mixed at room temperature for 1 minute with the “Virtis” ultradisperser. 0.2 g of methyl para-hydroxybenzoate, dissolved in 30.19 g of water beforehand, is added: the whole is mixed at room temperature for 1 minute with the “Virtis” ultradisperser. 0.1 g of sodium hyaluronate swollen beforehand in 10 g of water, marketed by the company “Biotechnology”, is added.
0.25 g of the mixture of vinylcarboxylic acids sold by the company “Goodrich” under the trade name “Carbopol 940”, swollen beforehand in 10 g of water, is then added. The whole is mixed at room temperature for 3 minutes with the “Virtis” ultradisperser at a speed of 20,000 rpm. 0.25 g of triethanolamine is added and the mixture is homogenized for 30 seconds with the “Virtis” ultradisperser. Finally, 10 g of dispersion of nanoparticles prepared in Example 3 are added. The whole is homogenized using a “Heidolph” paddle homogenizer at a speed of 800 rpm for 30 minutes.
A beige physiological fluid is thereby obtained, which will be applied once a day to the cleansed skin of the face, before and after periods of exposure to sunlight. It is found that, despite the high frequency of exposure to sunlight and the duration of such periods of exposure, the skin shows no trace of irritation.
Claims (11)
1. A process for the treatment of the upper layers of the epidermis comprising topically applying to the skin in an amount effective to treat the upper layers of the epidermis a composition comprising in a vehicle suitable for topical application to the skin, biodegradable polymer nanoparticles having a size ranging from 10 to 1,000 nm and encapsulating an oily phase comprising one or more of at least one active ingredient in the form of an oil or at least one active ingredient contained in an inactive carrier oil or an active oil, said active ingredient having a cosmetic action or a pharmaceutical action or both beneath the stratum corneum, said nanoparticles loaded with said active ingredient being present in an amount ranging from 0.1 to 20 percent by weight based on the total weight of said composition.
2. The process according to claim 1, wherein said biodegradable polymer constituting said nanoparticles is selected from the group consisting of a (C2-C12) alkyl cyanoacrylate, a poly-L-lactide, a poly-DL-lactide, a polyglycolide, a polycaprolactone, a polymer of 3-hydroxybutyric acid, a copoly (DL-lactide/glycolide) and a copoly (glycolide/caprolactone).
3. The process according to claim 1, wherein said polymer constituting said nanoparticles is a (C2-C6) alkyl cyanoacrylate.
4. The process according to claim 3, wherein the alkyl moiety of said cyanoacrylate is selected from the group consisting of ethyl, n-butyl, hexyl, isobutyl and isohexyl radicals.
5. The process for treatment of claim 1 wherein said active ingredient in the form of an oil or said active oil is selected from the group consisting of α-tocopherol, α-tocopherol acetate and tocopherol linoleate.
6. The process according to claim 1, wherein said active ingredient in the form of an oil or said active oil is selected from the group consisting of a triglyceride rich in linoleic acid or linolenic acid or both, pentaerythritol tetra (2-ethylhexanoate), clofibrate, fish oil, hazelnut oil, bisabolol farnesol, farnesyl acetate, ethyl linoleate and ethylhexyl paramethoxycinnamate.
7. The process according to claim 1 wherein said inactive carrier oil is selected from the group consisting of a simple triglyceride, a triglyceride modified by oxyethylenation, a volatile silicone oil and a mixture thereof.
8. The process of claim 1 wherein said active ingredient contained in an oil is selected from the group consisting of an emollient, a humectant, a free radical-inhibiting agent, an anti-inflammatory agent, a vitamin, a depigmenting agent, an anti-acne agent, an antiseborrhoeic agent, a keratolytic agent, a slimming agent and a skin coloring agent.
9. The process of claim 1 wherein the weight ratio of the biodegradable polymer of said nanoparticles to said oily phase ranges from 0.05 to 0.5.
10. The process of claim 1 wherein said composition is in the form of a physiological fluid, a lotion, an aqueous gel, an aqueous-alcoholic gel, an oil gel, a water-in-oil emulsion, an oil-in-water emulsion or an aqueous dispersion of vesicles, the constituent lipid of which is an ionic lipid or a non ionic lipid or a mixture of ionic and non ionic lipids, with or without an oily phase.
11. The process of claim 1 wherein at least a part of said nanoparticles contains at least one lipid lamella around the polymer membrane of the nanoparticle.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/195,081 US6203802B1 (en) | 1990-03-16 | 1994-02-14 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
US09/766,593 US20010010824A1 (en) | 1990-03-16 | 2001-01-23 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9003418 | 1990-03-16 | ||
FR909003418A FR2659554B1 (en) | 1990-03-16 | 1990-03-16 | COMPOSITION FOR THE COSMETIC AND / OR PHARMACEUTICAL TREATMENT OF THE TOP LAYERS OF THE EPIDERMIS BY TOPICAL APPLICATION TO THE SKIN AND PREPARATION METHOD THEREOF. |
US66830891A | 1991-03-13 | 1991-03-13 | |
US96153792A | 1992-10-15 | 1992-10-15 | |
US08/195,081 US6203802B1 (en) | 1990-03-16 | 1994-02-14 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US96153792A Continuation | 1990-03-16 | 1992-10-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/766,593 Continuation US20010010824A1 (en) | 1990-03-16 | 2001-01-23 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
Publications (1)
Publication Number | Publication Date |
---|---|
US6203802B1 true US6203802B1 (en) | 2001-03-20 |
Family
ID=9394836
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/195,081 Expired - Lifetime US6203802B1 (en) | 1990-03-16 | 1994-02-14 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
US09/766,593 Abandoned US20010010824A1 (en) | 1990-03-16 | 2001-01-23 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/766,593 Abandoned US20010010824A1 (en) | 1990-03-16 | 2001-01-23 | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process |
Country Status (10)
Country | Link |
---|---|
US (2) | US6203802B1 (en) |
EP (1) | EP0447318B1 (en) |
JP (1) | JP2676281B2 (en) |
AT (1) | ATE123219T1 (en) |
CA (1) | CA2038331C (en) |
DE (1) | DE69110070T2 (en) |
DK (1) | DK0447318T3 (en) |
ES (1) | ES2072563T3 (en) |
FR (1) | FR2659554B1 (en) |
ZA (1) | ZA911933B (en) |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444647B1 (en) * | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US20030185782A1 (en) * | 2002-01-18 | 2003-10-02 | Frederic Auguste | Cosmetic composition comprising a pro-adhesive material and a diffusing compound, which are separated |
US20030232918A1 (en) * | 2002-06-14 | 2003-12-18 | Amick David Richard | Aqueous nanaoparticle dispersions |
US6703003B1 (en) * | 1998-12-15 | 2004-03-09 | Three Bond Co., Ltd. | Manicure composition for nail |
US20040067245A1 (en) * | 2000-12-20 | 2004-04-08 | Harish Mahalingam | Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
US20040122385A1 (en) * | 2002-12-23 | 2004-06-24 | Kimberly-Clark Worldwide, Inc. | Absorbent articles including an odor absorbing and/or odor reducing additive |
US20040185022A1 (en) * | 2003-02-19 | 2004-09-23 | Steven Rubin | Regimen for acne treatment |
US20040223932A1 (en) * | 2003-05-05 | 2004-11-11 | Closure Medical Corporation | Adhesive treatment for acne |
WO2005012388A1 (en) * | 2003-07-30 | 2005-02-10 | Mnemoscience Gmbh | Cosmetic compositions comprising polyol/polyester block polymers |
WO2005012389A1 (en) * | 2003-07-30 | 2005-02-10 | Mnemoscience Gmbh | Method for treating hair with shape memory polymers |
AU2001240753B2 (en) * | 2000-03-02 | 2005-04-14 | Ethypharm S.A. | Lipid nanocapsules, preparation method and use as medicine |
EP1551570A2 (en) * | 2002-08-14 | 2005-07-13 | E.I. Du Pont De Nemours And Company | Solid flowable powder with high liquid loading |
US20060078522A1 (en) * | 2004-10-13 | 2006-04-13 | Gabin Vic | Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt |
US20060083781A1 (en) * | 2004-10-14 | 2006-04-20 | Shastri V P | Functionalized solid lipid nanoparticles and methods of making and using same |
WO2006047409A3 (en) * | 2004-10-22 | 2006-09-08 | Dynamis Therapeutics Inc | Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds |
US7153525B1 (en) | 2000-03-22 | 2006-12-26 | The University Of Kentucky Research Foundation | Microemulsions as precursors to solid nanoparticles |
US20070166275A1 (en) * | 2006-01-19 | 2007-07-19 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
US20080124350A1 (en) * | 2002-09-24 | 2008-05-29 | University Of Kentucky Research Foundation | Nanoparticle-based vaccine delivery system containing adjuvant |
US20080226708A1 (en) * | 2005-11-01 | 2008-09-18 | Shaow Burn Lin | Silicone Vesicles Containing Actives |
US20090004296A1 (en) * | 2006-01-04 | 2009-01-01 | Do-Coop Technologies Ltd. | Antiseptic Compositions and Methods of Using Same |
EP2011565A1 (en) | 2007-07-05 | 2009-01-07 | L'oreal | Core/skin type capsules and preparation method |
US20090081305A1 (en) * | 2001-12-12 | 2009-03-26 | Do-Coop Technologies Ltd. | Compositions and Methods for Enhancing In-Vivo Uptake of Pharmaceutical Agents |
US20090232855A1 (en) * | 2001-04-13 | 2009-09-17 | Sun Sang Kwon | Percutaneous controlled releasing material using nano-sized polymer particles and external application agent containing the same |
US20090253613A1 (en) * | 2006-01-04 | 2009-10-08 | Do-Coop Technologies Ltd. | Solid-Fluid Composition |
WO2009135855A2 (en) * | 2008-05-06 | 2009-11-12 | Glaxo Group Limited | Encapsulation of biologically active agents |
EP2134334A1 (en) * | 2007-03-16 | 2009-12-23 | Biolab Sanus Farmacêutica Ltda. | Nanoparticulated anesthetic composition for topic use |
US20100041103A1 (en) * | 2007-01-04 | 2010-02-18 | Do-Coop Technologies Ltd. | Composition and method for enhancing cell growth and cell fusion |
US20100040883A1 (en) * | 2001-12-19 | 2010-02-18 | Mccarthy Stephen P | Polysaccharide-containing block copolymer particles and uses thereof |
US20100086929A1 (en) * | 2007-01-04 | 2010-04-08 | Do-Coop Technologies Ltd. | Detection of analytes |
US20100247563A1 (en) * | 2009-03-30 | 2010-09-30 | Mary Kay Inc. | Topical skin care formulations |
WO2011028601A2 (en) | 2009-08-26 | 2011-03-10 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
JP2011522792A (en) * | 2008-05-06 | 2011-08-04 | グラクソ グループ リミテッド | Encapsulating bioactive agents |
WO2011103449A2 (en) | 2010-02-19 | 2011-08-25 | Mary Kay Inc. | Topical skin care formulation |
US20110217366A1 (en) * | 1997-05-19 | 2011-09-08 | Dainippon Sumitomo Pharma Co., Ltd. | Immunopotentiating composition |
US8048456B2 (en) | 2009-08-28 | 2011-11-01 | Mary Kay Inc. | Skin care formulations |
WO2011159439A2 (en) | 2010-06-16 | 2011-12-22 | Mary Kay Inc. | Skin moisturizer |
WO2012033634A2 (en) | 2010-09-09 | 2012-03-15 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
WO2012033646A2 (en) | 2010-09-10 | 2012-03-15 | Mary Kay Inc. | Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof |
WO2013086518A1 (en) | 2011-12-09 | 2013-06-13 | Mary Kay Inc. | Skin care formulation |
DE202012012769U1 (en) | 2011-04-06 | 2014-01-29 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE202012012784U1 (en) | 2011-04-21 | 2014-01-30 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE202012012873U1 (en) | 2011-03-28 | 2014-02-03 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE202012012834U1 (en) | 2011-06-08 | 2014-03-31 | Mary Kay Inc. | Sunscreen formulations |
DE202012013018U1 (en) | 2011-12-19 | 2014-08-20 | Mary Kay Inc. | Combination of plant extracts to improve the skin tone |
WO2014150545A1 (en) | 2013-03-15 | 2014-09-25 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
WO2014159238A1 (en) | 2013-03-14 | 2014-10-02 | Mary Kay Inc. | Cosmetic compositions |
WO2015023926A1 (en) | 2013-08-15 | 2015-02-19 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US9005588B2 (en) | 2011-12-22 | 2015-04-14 | Mary Kay Inc. | Substantive sunscreen formulation |
DE202015004872U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | Topical skin composition and its use |
DE202015004866U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | Topical skin composition and its use |
DE202015004868U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | Topical skin composition and its use |
DE202015004867U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | lipstick composition |
US9402794B2 (en) | 2011-12-07 | 2016-08-02 | Mary Kay Inc. | Topical skin care formulation |
WO2016161074A1 (en) | 2015-03-31 | 2016-10-06 | Gojo Industries, Inc. | Synergistic compositions and methods for mitigating skin irritation and enhancing skin barrier function |
DE202015009366U1 (en) | 2014-07-11 | 2017-04-10 | Mary Kay Inc. | Pore minimizer |
US9968533B2 (en) * | 2008-10-10 | 2018-05-15 | Biolab Sanus Farmacêutical Ltda | Nanoparticle system comprising oil and UV filter |
US10532019B2 (en) | 2005-12-01 | 2020-01-14 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US11007134B1 (en) | 2020-03-31 | 2021-05-18 | L'oreal | Ceramide containing capsules, ceramide compositions, and cosmetic compositions thereof |
CN113194907A (en) * | 2018-08-10 | 2021-07-30 | 瞬息方案公司 | Particles comprising a colorant and methods of use thereof |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686249A1 (en) * | 1992-01-16 | 1993-07-23 | Olivier Josette | PREPARATION FOR CUTANEOUS USE BASED ON LIPOSOMES. |
ES2051214B1 (en) * | 1992-02-27 | 1994-12-16 | Quintela Manuel Arturo Lopez | PROCEDURE FOR OBTAINING NANOPARTICLES BY POLYMERIZATION IN MICROEMULSIONS. |
WO1994015590A1 (en) * | 1993-01-11 | 1994-07-21 | Abacol Limited | Small diameter nanocapsules, process for their preparation and applications thereof |
GB9300875D0 (en) * | 1993-01-18 | 1993-03-10 | Ucb Sa | Nanocapsule containing pharmaceutical compositions |
US5610199A (en) * | 1994-03-22 | 1997-03-11 | Estee Lauder Inc. | Solid lipophilic composition and process for its preparation |
FR2734480B1 (en) * | 1995-05-22 | 1997-08-08 | Gueyne Edith | COSMETIC COMPOSITION FOR THE SKIN COMPRISING A NANODISPERSION OF FATTY BODIES IN WATER |
DE19520237A1 (en) * | 1995-06-02 | 1996-12-05 | Beiersdorf Ag | Cosmetic or dermatological preparations containing oligomers or polymers of alpha-hydroxycarboxylic acids |
FR2738743B1 (en) * | 1995-09-19 | 1997-11-14 | Oreal | USE OF ASCORBIC ACID AS AN ACTIVE INGREDIENT FOR THE TREATMENT OF SEBORRHEA IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION |
FR2742677B1 (en) | 1995-12-21 | 1998-01-16 | Oreal | LAMELLAR PHASE COATED NANOPARTICLES BASED ON SILICONE SURFACTANT AND COMPOSITIONS CONTAINING THEM |
US6060515A (en) * | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
USRE37770E1 (en) | 1997-01-24 | 2002-06-25 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
EP1019059A4 (en) * | 1997-01-24 | 2004-01-14 | Univ California | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION |
FR2787730B1 (en) | 1998-12-29 | 2001-02-09 | Oreal | POLY (ALKYLENE ADIPATE) NANOCAPSULES, PROCESS FOR THEIR PREPARATION AND COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING THEM |
FR2787729B1 (en) * | 1998-12-29 | 2001-01-26 | Oreal | NANOCAPSULES BASED ON HYDRODISPERSIBLE ANIONIC POLYMERS, THEIR PREPARATION METHOD AND COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING THEM |
FR2790405B1 (en) * | 1999-03-02 | 2001-04-20 | Oreal | NANOCAPSULES BASED ON DENDRITIC POLYMERS |
US6284802B1 (en) | 1999-04-19 | 2001-09-04 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue |
ES2269166T3 (en) * | 1999-07-13 | 2007-04-01 | Clr Chemisches Laboratorium Dr. Kurt Richter Gmbh | AGENTS WITH ABSORBENT AND / OR REFLECTIVE UV RADIATION EFFECT FOR THE PROTECTION AGAINST HARMFUL UV RADIATION FOR HEALTH AND STRENGTHENING OF THE NATURAL CUTANEOUS BARRIER. |
IT1318380B1 (en) | 2000-03-09 | 2003-08-25 | Intercos Italiana | COATED COSMETIC POWDER. |
DE10063428A1 (en) * | 2000-12-20 | 2002-07-11 | Henkel Kgaa | Dispersions of nanoparticulate fragrance-containing composite materials |
DE10111508A1 (en) * | 2001-03-09 | 2002-09-26 | Henkel Kgaa | Modified cyanoacrylate esters, nano- or microcapsules made from them and their use in detergents or cleaning agents |
WO2003020226A2 (en) * | 2001-08-31 | 2003-03-13 | L'oreal S.A. | Cosmetic compositions comprising nanoparticles and processes for using the same |
DE10150730A1 (en) * | 2001-10-13 | 2003-04-17 | Cognis Deutschland Gmbh | Fruit acid esters are used as fat-replacement agents in surfactant-containing cosmetic or pharmaceutical compositions, optionally together with fatty alcohols |
ATE424815T1 (en) * | 2001-12-03 | 2009-03-15 | Dor Biopharma Inc | STABILIZED REVERSE MICELLAR COMPOSITIONS AND USE THEREOF |
FR2836381B1 (en) * | 2002-02-22 | 2004-09-10 | Oreal | POLYESTER POLYOL-BASED NANOCAPSULES, AND COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING THEM |
FR2839517A1 (en) * | 2002-05-07 | 2003-11-14 | Centre Nat Rech Scient | NOVEL BIODEGRADABLE SURFACTANTS OF THE AMPHIPHILIC COPOLYMER TYPE COMPRISING HYDROPHOBIC SEGMENTS AND OLIGO AND / OR POLYSACCHARIDES |
IL150906A0 (en) * | 2002-07-25 | 2003-02-12 | Yissum Res Dev Co | Diagnostic microspheres |
US20050051968A1 (en) * | 2002-11-13 | 2005-03-10 | Froesel David William | Washer toss game |
FR2859630A1 (en) * | 2003-09-15 | 2005-03-18 | Oreal | Fluid, topical cosmetic or dermatological oil-in-water emulsions, e.g. for skin care, cleansing or make-up removal, containing mineral oil and imidazolidinyl urea as stabilizer |
JP4851067B2 (en) * | 2004-01-28 | 2012-01-11 | ホソカワミクロン株式会社 | Nanoparticle-containing composition and method for producing the same |
FR2872703B1 (en) * | 2004-07-07 | 2006-10-06 | Ethypharm Sa | COMPOSITE POLYMERIC NANOPARTICLES |
CN1733313A (en) * | 2004-08-11 | 2006-02-15 | 张阳德 | Process for preparing poly n-butyl cyan acrylate nanometer particle |
JP2008513363A (en) * | 2004-09-14 | 2008-05-01 | ナノデル テクノロジーズ ゲーエムベーハー | Delivery vehicle comprising nanoparticles |
JP4575755B2 (en) * | 2004-11-22 | 2010-11-04 | 興和株式会社 | Liquid for external use |
FR2903599B1 (en) * | 2006-07-13 | 2012-08-31 | Oreal | AQUEOUS CONTINUOUS PHASE COSMETIC COMPOSITION COMPRISING AT LEAST ONE THERMOGELIFYING POLYMER, AT LEAST ONE VOLATILE ORGANIC SOLVENT MISCIBLE IN WATER AND AT LEAST ONE UV RADIATION ABSORBING AGENT. |
FR2910286B1 (en) | 2006-12-20 | 2009-04-17 | Oreal | COMPOSITION COMPRISING ENCAPSULATED SILICONE COMPOUNDS |
FR2910345A1 (en) | 2006-12-20 | 2008-06-27 | Oreal | Core-shell particles useful for preparing cosmetic or therapeutic compositions have a shell comprising a polymer film formed by reaction of two silicones |
FR2910283A1 (en) * | 2006-12-20 | 2008-06-27 | Oreal | Cosmetic composition useful for treating keratinous fiber comprises polymer soluble in composition and obtained from dielectrophilic monomer and optionally (meth) acrylic, (meth) acrylate or vinyl monomers other than dielectrophilic monomer |
US8679539B2 (en) * | 2007-01-31 | 2014-03-25 | Tong Shen Enterprise Co., Ltd. | Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof |
EP2120845B1 (en) * | 2007-02-21 | 2012-10-24 | ROVI Cosmetics International GmbH | Nanoparticles for use in cosmetic and dermatological formulations |
FR2914189A1 (en) | 2007-03-26 | 2008-10-03 | Oreal | USE OF A LIPOPOLYSACCHARIDE FRACTION OF VITREOSCILLA FILIFORMIS AS AGENT STIMULATING THE SYNTHESIS OF ANTIMICROBIAL PEPTIDES OF THE SKIN. |
FR2918885B1 (en) | 2007-07-17 | 2009-08-28 | Oreal | USE OF CULTIVATED BACTERIUM EXTRACT IN THERMAL WATER TO DECREASE POCKETS AND / OR PERIOCULAR CERNES |
FR2920309B1 (en) | 2007-08-28 | 2010-05-28 | Galderma Res & Dev | USE OF TRAVOPROST TO TREAT THE FALL OF HAIR |
US8846063B2 (en) * | 2008-12-16 | 2014-09-30 | Kimberly-Clark Worldwide, Inc. | Personal care composition containing a volatile and a terpene alcohol |
FR2954679B1 (en) | 2009-12-31 | 2013-11-29 | Oreal | DEVICE FOR PREPARING A COSMETIC COMPOSITION, NECESSARY AND ASSOCIATED METHOD. |
FR2967573B1 (en) | 2010-11-23 | 2012-11-09 | Rhodia Poliamida E Especialidades Ltda | COSMETIC KIT AND USE TO ENHANCE THE SKIN'S APPEARANCE |
BR102012022036B1 (en) * | 2012-08-31 | 2019-10-01 | Biolab Sanus Farmacêutica Ltda. | FINASTERIDE AND MINOXIDIL POLYMERIC NANOParticle, PROCESS OF PREPARATION, WATER-CONTAINING SUSPENSION, PHARMACEUTICAL COMPOSITION, AND ITS USE |
JP6847668B2 (en) * | 2015-01-27 | 2021-03-24 | 昇一 城武 | A therapeutic or preventive agent for dermatitis containing nanoparticles as an active ingredient |
WO2018180966A1 (en) * | 2017-03-28 | 2018-10-04 | 富士フイルム株式会社 | Microcapsule and method for manufacturing same |
KR102093827B1 (en) * | 2018-06-21 | 2020-03-26 | 아데카코리아 주식회사 | Cosmetic compositions containing poly(butyl cyanoacrylate) |
US11957793B2 (en) | 2018-08-23 | 2024-04-16 | Sintef Tto As | Nanoparticles |
CN113730652B (en) * | 2021-09-01 | 2022-12-02 | 北京大清生物技术股份有限公司 | Mixed gel for injection and preparation method and application thereof |
WO2023048002A1 (en) * | 2021-09-24 | 2023-03-30 | 三菱鉛筆株式会社 | Reducing particle dispersion |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3516941A (en) | 1966-07-25 | 1970-06-23 | Minnesota Mining & Mfg | Microcapsules and process of making |
US3965033A (en) | 1970-07-27 | 1976-06-22 | Fuji Photo Film Co., Ltd. | Process for the production of oil-containing microcapsules |
US4329332A (en) | 1978-07-19 | 1982-05-11 | Patrick Couvreur | Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them |
FR2515960A1 (en) | 1981-11-06 | 1983-05-13 | Alkhouri Fallouh Nazir | Biodegradable nano:capsules contg. biologically active cpd. - having envelope of polymerised alkyl cyanoacrylate |
US4489055A (en) * | 1978-07-19 | 1984-12-18 | N.V. Sopar S.A. | Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use |
EP0274961A1 (en) | 1986-12-31 | 1988-07-20 | Centre National De La Recherche Scientifique (Cnrs) | Process for preparing a colloidal and disperse system in the shape of nanocapsules |
EP0330180A1 (en) | 1988-02-24 | 1989-08-30 | Biomaterials Universe, Inc. | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same |
US4880617A (en) | 1981-03-23 | 1989-11-14 | Dow Corning Corporation | Lattice-entrapped composition |
US4897267A (en) | 1987-07-30 | 1990-01-30 | Ire-Celltarg S.A. | Microparticles comprising a biodegradable polymer controlling the release of an antimalaria active principle, pharmaceutical compositions comprising it and process for its preparation |
US4917892A (en) | 1988-06-28 | 1990-04-17 | Temple University | Encapsulated topical delivery system |
US4976961A (en) | 1986-07-18 | 1990-12-11 | Minnesota Mining And Manufacturing Company | Encapsulated cosmetic materials and process of making |
US5118528A (en) * | 1986-12-31 | 1992-06-02 | Centre National De La Recherche Scientifique | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5133908A (en) * | 1986-12-31 | 1992-07-28 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5139783A (en) | 1989-04-07 | 1992-08-18 | L'oreal | Process for the preparation of alginate capsules, apparatus for producing said capsules and cosmetic compositions containing said capsules |
US5919487A (en) * | 1995-12-21 | 1999-07-06 | L'oreal | Nanoparticles coated with a lamellar phase based on silicone surfactant and compositions containing them |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
JPS6061521A (en) * | 1983-09-16 | 1985-04-09 | Kyowa Hakko Kogyo Co Ltd | Microencapsulated pharmaceutical |
US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
JPS6443343A (en) * | 1987-08-06 | 1989-02-15 | Pola Chem Ind Inc | Microcapsules and their production |
IT1219587B (en) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
FR2643906B1 (en) * | 1989-03-02 | 1991-05-24 | Rhone Poulenc Chimie | POLYESTER-SILICONE BLOCK COPOLYMER DEGRADABLE BY HYDROLYSIS |
-
1990
- 1990-03-16 FR FR909003418A patent/FR2659554B1/en not_active Expired - Fee Related
-
1991
- 1991-03-13 ES ES91400684T patent/ES2072563T3/en not_active Expired - Lifetime
- 1991-03-13 EP EP91400684A patent/EP0447318B1/en not_active Expired - Lifetime
- 1991-03-13 DE DE69110070T patent/DE69110070T2/en not_active Expired - Lifetime
- 1991-03-13 AT AT91400684T patent/ATE123219T1/en not_active IP Right Cessation
- 1991-03-13 DK DK91400684.6T patent/DK0447318T3/en active
- 1991-03-15 JP JP3216760A patent/JP2676281B2/en not_active Expired - Lifetime
- 1991-03-15 CA CA002038331A patent/CA2038331C/en not_active Expired - Fee Related
- 1991-03-15 ZA ZA911933A patent/ZA911933B/en unknown
-
1994
- 1994-02-14 US US08/195,081 patent/US6203802B1/en not_active Expired - Lifetime
-
2001
- 2001-01-23 US US09/766,593 patent/US20010010824A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3516941A (en) | 1966-07-25 | 1970-06-23 | Minnesota Mining & Mfg | Microcapsules and process of making |
US3965033A (en) | 1970-07-27 | 1976-06-22 | Fuji Photo Film Co., Ltd. | Process for the production of oil-containing microcapsules |
US4329332A (en) | 1978-07-19 | 1982-05-11 | Patrick Couvreur | Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them |
US4489055A (en) * | 1978-07-19 | 1984-12-18 | N.V. Sopar S.A. | Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use |
US4880617A (en) | 1981-03-23 | 1989-11-14 | Dow Corning Corporation | Lattice-entrapped composition |
FR2515960A1 (en) | 1981-11-06 | 1983-05-13 | Alkhouri Fallouh Nazir | Biodegradable nano:capsules contg. biologically active cpd. - having envelope of polymerised alkyl cyanoacrylate |
US4976961A (en) | 1986-07-18 | 1990-12-11 | Minnesota Mining And Manufacturing Company | Encapsulated cosmetic materials and process of making |
US5118528A (en) * | 1986-12-31 | 1992-06-02 | Centre National De La Recherche Scientifique | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
EP0274961A1 (en) | 1986-12-31 | 1988-07-20 | Centre National De La Recherche Scientifique (Cnrs) | Process for preparing a colloidal and disperse system in the shape of nanocapsules |
US5133908A (en) * | 1986-12-31 | 1992-07-28 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US4897267A (en) | 1987-07-30 | 1990-01-30 | Ire-Celltarg S.A. | Microparticles comprising a biodegradable polymer controlling the release of an antimalaria active principle, pharmaceutical compositions comprising it and process for its preparation |
EP0330180A1 (en) | 1988-02-24 | 1989-08-30 | Biomaterials Universe, Inc. | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same |
US4917892A (en) | 1988-06-28 | 1990-04-17 | Temple University | Encapsulated topical delivery system |
US5139783A (en) | 1989-04-07 | 1992-08-18 | L'oreal | Process for the preparation of alginate capsules, apparatus for producing said capsules and cosmetic compositions containing said capsules |
US5919487A (en) * | 1995-12-21 | 1999-07-06 | L'oreal | Nanoparticles coated with a lamellar phase based on silicone surfactant and compositions containing them |
Non-Patent Citations (1)
Title |
---|
French Search Report of FR 90 03418. |
Cited By (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110217366A1 (en) * | 1997-05-19 | 2011-09-08 | Dainippon Sumitomo Pharma Co., Ltd. | Immunopotentiating composition |
US6703003B1 (en) * | 1998-12-15 | 2004-03-09 | Three Bond Co., Ltd. | Manicure composition for nail |
US6444647B1 (en) * | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
AU2001240753B2 (en) * | 2000-03-02 | 2005-04-14 | Ethypharm S.A. | Lipid nanocapsules, preparation method and use as medicine |
US20070154907A1 (en) * | 2000-03-22 | 2007-07-05 | Mumper Russell J | Microemulsions as precursors to solid nanoparticles |
US20060292183A1 (en) * | 2000-03-22 | 2006-12-28 | Mumper Russell J | Microemulsions as precursors to solid nanoparticles |
US7153525B1 (en) | 2000-03-22 | 2006-12-26 | The University Of Kentucky Research Foundation | Microemulsions as precursors to solid nanoparticles |
US20040067245A1 (en) * | 2000-12-20 | 2004-04-08 | Harish Mahalingam | Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
US20090232855A1 (en) * | 2001-04-13 | 2009-09-17 | Sun Sang Kwon | Percutaneous controlled releasing material using nano-sized polymer particles and external application agent containing the same |
US20090081305A1 (en) * | 2001-12-12 | 2009-03-26 | Do-Coop Technologies Ltd. | Compositions and Methods for Enhancing In-Vivo Uptake of Pharmaceutical Agents |
US20100267007A1 (en) * | 2001-12-12 | 2010-10-21 | Do-Coop Technologies Ltd. | Solid-fluid composition and uses thereof |
US7763663B2 (en) | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US20100040883A1 (en) * | 2001-12-19 | 2010-02-18 | Mccarthy Stephen P | Polysaccharide-containing block copolymer particles and uses thereof |
US20030185782A1 (en) * | 2002-01-18 | 2003-10-02 | Frederic Auguste | Cosmetic composition comprising a pro-adhesive material and a diffusing compound, which are separated |
US20030232918A1 (en) * | 2002-06-14 | 2003-12-18 | Amick David Richard | Aqueous nanaoparticle dispersions |
US7244784B2 (en) | 2002-06-14 | 2007-07-17 | Rohm And Haas Company | Aqueous nanoparticle dispersions |
EP1551570A2 (en) * | 2002-08-14 | 2005-07-13 | E.I. Du Pont De Nemours And Company | Solid flowable powder with high liquid loading |
US20050233074A1 (en) * | 2002-08-14 | 2005-10-20 | Dalziel Sean M | Solid flowable powder with high liquid loading |
EP1551570A4 (en) * | 2002-08-14 | 2008-04-09 | Du Pont | Solid flowable powder with high liquid loading |
US20080124350A1 (en) * | 2002-09-24 | 2008-05-29 | University Of Kentucky Research Foundation | Nanoparticle-based vaccine delivery system containing adjuvant |
US20040122385A1 (en) * | 2002-12-23 | 2004-06-24 | Kimberly-Clark Worldwide, Inc. | Absorbent articles including an odor absorbing and/or odor reducing additive |
US20040185022A1 (en) * | 2003-02-19 | 2004-09-23 | Steven Rubin | Regimen for acne treatment |
US20040223932A1 (en) * | 2003-05-05 | 2004-11-11 | Closure Medical Corporation | Adhesive treatment for acne |
WO2004100889A3 (en) * | 2003-05-12 | 2005-03-24 | Avon Prod Inc | Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
WO2005012389A1 (en) * | 2003-07-30 | 2005-02-10 | Mnemoscience Gmbh | Method for treating hair with shape memory polymers |
WO2005012388A1 (en) * | 2003-07-30 | 2005-02-10 | Mnemoscience Gmbh | Cosmetic compositions comprising polyol/polyester block polymers |
US20060078522A1 (en) * | 2004-10-13 | 2006-04-13 | Gabin Vic | Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt |
US20060083781A1 (en) * | 2004-10-14 | 2006-04-20 | Shastri V P | Functionalized solid lipid nanoparticles and methods of making and using same |
WO2006047409A3 (en) * | 2004-10-22 | 2006-09-08 | Dynamis Therapeutics Inc | Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds |
US20080226708A1 (en) * | 2005-11-01 | 2008-09-18 | Shaow Burn Lin | Silicone Vesicles Containing Actives |
US10532019B2 (en) | 2005-12-01 | 2020-01-14 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US10576034B2 (en) | 2005-12-01 | 2020-03-03 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US20090253613A1 (en) * | 2006-01-04 | 2009-10-08 | Do-Coop Technologies Ltd. | Solid-Fluid Composition |
US20090004296A1 (en) * | 2006-01-04 | 2009-01-01 | Do-Coop Technologies Ltd. | Antiseptic Compositions and Methods of Using Same |
US10668124B2 (en) | 2006-01-19 | 2020-06-02 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
EP2944313A1 (en) | 2006-01-19 | 2015-11-18 | Mary Kay, Inc. | Compositions comprising kakadu plum extract or acai berry extract |
US20070166275A1 (en) * | 2006-01-19 | 2007-07-19 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
US10130673B2 (en) | 2006-01-19 | 2018-11-20 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
US10918591B2 (en) | 2006-01-19 | 2021-02-16 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
US10675323B2 (en) | 2006-01-19 | 2020-06-09 | Mary Kay Inc. | Topical compositions comprising acai berry extract |
US20100086929A1 (en) * | 2007-01-04 | 2010-04-08 | Do-Coop Technologies Ltd. | Detection of analytes |
US20100041103A1 (en) * | 2007-01-04 | 2010-02-18 | Do-Coop Technologies Ltd. | Composition and method for enhancing cell growth and cell fusion |
EP2134334A4 (en) * | 2007-03-16 | 2013-04-24 | Biolab Sanus Farmaceutica Ltda | Nanoparticulated anesthetic composition for topic use |
EP2134334A1 (en) * | 2007-03-16 | 2009-12-23 | Biolab Sanus Farmacêutica Ltda. | Nanoparticulated anesthetic composition for topic use |
EP2011565A1 (en) | 2007-07-05 | 2009-01-07 | L'oreal | Core/skin type capsules and preparation method |
JP2011522792A (en) * | 2008-05-06 | 2011-08-04 | グラクソ グループ リミテッド | Encapsulating bioactive agents |
JP2011519894A (en) * | 2008-05-06 | 2011-07-14 | グラクソ グループ リミテッド | Encapsulating bioactive agents |
WO2009135855A3 (en) * | 2008-05-06 | 2011-01-27 | Glaxo Group Limited | Encapsulation of biologically active agents |
WO2009135855A2 (en) * | 2008-05-06 | 2009-11-12 | Glaxo Group Limited | Encapsulation of biologically active agents |
US10016350B2 (en) | 2008-10-10 | 2018-07-10 | Biolab Sanus Farmacêutica Ltda | Nanoparticle system comprising oil and UV filter |
US9968533B2 (en) * | 2008-10-10 | 2018-05-15 | Biolab Sanus Farmacêutical Ltda | Nanoparticle system comprising oil and UV filter |
US8993006B2 (en) | 2009-03-30 | 2015-03-31 | Mary Kay Inc. | Topical skin care formulations |
US20100247563A1 (en) * | 2009-03-30 | 2010-09-30 | Mary Kay Inc. | Topical skin care formulations |
US8178106B2 (en) | 2009-03-30 | 2012-05-15 | Mary Kay Inc. | Topical skin care formulations |
WO2011028601A2 (en) | 2009-08-26 | 2011-03-10 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
US8048456B2 (en) | 2009-08-28 | 2011-11-01 | Mary Kay Inc. | Skin care formulations |
US8691300B2 (en) | 2009-08-28 | 2014-04-08 | Mary Kay Inc. | Skin care formulations |
US11679284B2 (en) | 2009-08-28 | 2023-06-20 | Mary Kay Inc. | Skin care formulations |
US11596813B2 (en) | 2009-08-28 | 2023-03-07 | Mary Kay Inc. | Skin care formulations |
US8895082B2 (en) | 2009-08-28 | 2014-11-25 | Mary Kay Inc. | Skin care formulations |
US11123578B2 (en) | 2009-08-28 | 2021-09-21 | Mary Kay Inc. | Skin care formulations |
US9833642B2 (en) | 2009-08-28 | 2017-12-05 | Mary Kay Inc. | Skin care formulations |
US10434340B2 (en) | 2009-08-28 | 2019-10-08 | Mary Kay Inc. | Skin care formulations |
WO2011103449A2 (en) | 2010-02-19 | 2011-08-25 | Mary Kay Inc. | Topical skin care formulation |
US8986720B2 (en) | 2010-06-16 | 2015-03-24 | Mary Kay Inc. | Skin moisturizer |
WO2011159439A2 (en) | 2010-06-16 | 2011-12-22 | Mary Kay Inc. | Skin moisturizer |
WO2012033634A2 (en) | 2010-09-09 | 2012-03-15 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
WO2012033646A2 (en) | 2010-09-10 | 2012-03-15 | Mary Kay Inc. | Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof |
DE202012012873U1 (en) | 2011-03-28 | 2014-02-03 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE202012012769U1 (en) | 2011-04-06 | 2014-01-29 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE202012012784U1 (en) | 2011-04-21 | 2014-01-30 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE202012012834U1 (en) | 2011-06-08 | 2014-03-31 | Mary Kay Inc. | Sunscreen formulations |
US9402794B2 (en) | 2011-12-07 | 2016-08-02 | Mary Kay Inc. | Topical skin care formulation |
DE202012013021U1 (en) | 2011-12-09 | 2014-11-28 | Mary Kay Inc. | Skin care formulation |
WO2013086518A1 (en) | 2011-12-09 | 2013-06-13 | Mary Kay Inc. | Skin care formulation |
DE202012013018U1 (en) | 2011-12-19 | 2014-08-20 | Mary Kay Inc. | Combination of plant extracts to improve the skin tone |
US9005588B2 (en) | 2011-12-22 | 2015-04-14 | Mary Kay Inc. | Substantive sunscreen formulation |
US10842837B2 (en) | 2013-03-14 | 2020-11-24 | Mary Kay Inc. | Cosmetic compositions |
US9333230B2 (en) | 2013-03-14 | 2016-05-10 | Mary Kay Inc. | Cosmetic compositions |
WO2014159238A1 (en) | 2013-03-14 | 2014-10-02 | Mary Kay Inc. | Cosmetic compositions |
US11547733B2 (en) | 2013-03-14 | 2023-01-10 | Mary Kay Inc. | Cosmetic compositions |
KR20220125370A (en) | 2013-03-14 | 2022-09-14 | 마리 케이 인코포레이티드 | Cosmetic compositions |
US10111919B2 (en) | 2013-03-14 | 2018-10-30 | Mary Kay Inc. | Cosmetic compositions |
KR20150127282A (en) | 2013-03-14 | 2015-11-16 | 마리 케이 인코포레이티드 | Cosmetic compositions |
KR20200138834A (en) | 2013-03-14 | 2020-12-10 | 마리 케이 인코포레이티드 | Cosmetic compositions |
KR20150132516A (en) | 2013-03-15 | 2015-11-25 | 마리 케이 인코포레이티드 | Cosmetic compositions and uses thereof |
US11723845B2 (en) | 2013-03-15 | 2023-08-15 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US10299994B2 (en) | 2013-03-15 | 2019-05-28 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US9463155B2 (en) | 2013-03-15 | 2016-10-11 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
WO2014150545A1 (en) | 2013-03-15 | 2014-09-25 | Mary Kay Inc. | Cosmetic compositions and uses thereof |
US11135139B2 (en) | 2013-03-15 | 2021-10-05 | Belaj Innovations Llc | Cosmetic compositions and uses thereof |
US10391049B2 (en) | 2013-08-15 | 2019-08-27 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US9833404B2 (en) | 2013-08-15 | 2017-12-05 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US10213377B2 (en) | 2013-08-15 | 2019-02-26 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US10888509B2 (en) | 2013-08-15 | 2021-01-12 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US9642793B2 (en) | 2013-08-15 | 2017-05-09 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US11911494B2 (en) | 2013-08-15 | 2024-02-27 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
US11497697B2 (en) | 2013-08-15 | 2022-11-15 | Allustra Technologies Llc | Topical skin compositions for treating wrinkles |
WO2015023926A1 (en) | 2013-08-15 | 2015-02-19 | Mary Kay Inc. | Topical skin compositions for treating wrinkles |
DE202015004868U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | Topical skin composition and its use |
EP3909562A2 (en) | 2014-07-11 | 2021-11-17 | Mary Kay Inc. | Cosmetic compositions for the lip |
DE202015004866U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | Topical skin composition and its use |
DE202015004867U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | lipstick composition |
DE202015004872U1 (en) | 2014-07-11 | 2015-12-23 | Mary Kay Inc. | Topical skin composition and its use |
DE202015009366U1 (en) | 2014-07-11 | 2017-04-10 | Mary Kay Inc. | Pore minimizer |
WO2016161074A1 (en) | 2015-03-31 | 2016-10-06 | Gojo Industries, Inc. | Synergistic compositions and methods for mitigating skin irritation and enhancing skin barrier function |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
CN113194907A (en) * | 2018-08-10 | 2021-07-30 | 瞬息方案公司 | Particles comprising a colorant and methods of use thereof |
US11007134B1 (en) | 2020-03-31 | 2021-05-18 | L'oreal | Ceramide containing capsules, ceramide compositions, and cosmetic compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
ZA911933B (en) | 1991-12-24 |
CA2038331C (en) | 1998-10-27 |
ATE123219T1 (en) | 1995-06-15 |
ES2072563T3 (en) | 1995-07-16 |
FR2659554B1 (en) | 1994-09-30 |
JP2676281B2 (en) | 1997-11-12 |
DE69110070D1 (en) | 1995-07-06 |
JPH05148129A (en) | 1993-06-15 |
DE69110070T2 (en) | 1995-10-12 |
CA2038331A1 (en) | 1991-09-17 |
US20010010824A1 (en) | 2001-08-02 |
FR2659554A1 (en) | 1991-09-20 |
DK0447318T3 (en) | 1995-10-02 |
EP0447318A1 (en) | 1991-09-18 |
EP0447318B1 (en) | 1995-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6203802B1 (en) | Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process | |
US5919487A (en) | Nanoparticles coated with a lamellar phase based on silicone surfactant and compositions containing them | |
US5556617A (en) | Composition providing a lasting cosmetic and/or pharmaceutical treatment of the upper epidermal layers by topical application on the skin | |
JP2674961B2 (en) | Protective, nourishing and tightening composition for simultaneous treatment of superficial and deep layers of skin and method of protecting, nourishing and tightening skin | |
KR100463167B1 (en) | Percutaneous Controlled Releasing Material Using Nano-sized Polymeric Particles and External Application Agent Containing the Same | |
JP2736312B2 (en) | Use of spin trap in cosmetic or dermatological composition, its composition and cosmetic treatment method using the same | |
RU2124884C1 (en) | Cosmetic or dermatological composition and a method of its preparing | |
US6328987B1 (en) | Cosmetic skin care compositions containing alpha interferon | |
EP0661036B1 (en) | Antiacne composition for the simultaneous treatment of superficial and lower layers of the skin | |
EP0728459B1 (en) | Acidic composition based on lipid vesicles and its use in topical application | |
RU2421216C2 (en) | Compositions containing at least one naphthoic acid derivative and at least one compound of polyurethane polymer or its derivative, methods of producing and applying thereof | |
US20080193393A1 (en) | Delivery System for Topically Applied Compounds | |
JPH10513188A (en) | Composition for makeup makeup | |
JP2003510241A (en) | Oily / shining skin-regulating coating composition | |
KR100483391B1 (en) | Stabilized Whitening Compositions and Method of Preparing Same | |
JP2004175750A (en) | Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them | |
KR100792048B1 (en) | Topical delivery system containing colloidal crystalline arrays | |
JPH0873370A (en) | Composition for make-up or dermatology containing plant extract in capsule | |
KR102105210B1 (en) | Cosmetic composition of oil in water emulsion stabilized retinoids derivative | |
JP2006515020A (en) | Cosmetic composition for caring for oily skin containing carboxyl fatty acids or derivatives thereof | |
KR20040105169A (en) | Preparation method of stable nano-emulsion utilizing arbutin and cosmetic formulations containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |